Beam Therapeutics (BEAM) 10-Q 7 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Oct. 31, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Trading Symbol	BEAM
Entity Registrant Name	Beam Therapeutics Inc.
Entity Central Index Key	0001745999
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Title of 12(b) Security	Common Stock, par value $0.01 per share
Security Exchange Name	NASDAQ
Entity File Number	001-39208
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-5238376
Entity Address, Address Line One	238 Main Street
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02142
City Area Code	857
Local Phone Number	327-8775
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		70,468,961

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 156,511	$ 559,994
Marketable securities	938,043	405,653
Collaboration receivable		300,000
Prepaid expenses and other current assets	14,358	7,360
Total current assets	1,108,912	1,273,007
Property and equipment, net	111,180	84,258
Restricted cash	12,750	12,746
Operating lease right-of-use assets	115,534	102,718
Other assets	1,874	1,724
Total assets	1,350,250	1,474,453
Current liabilities:
Accounts payable	7,024	7,474
Accrued expenses and other current liabilities	38,600	28,921
Accrued sub-license fees		38,743
Derivative liabilities	21,300	42,200
Current portion of deferred revenue	159,902	86,270
Current portion of lease liability	9,823	7,540
Current portion of equipment financing liability	2,210	2,287
Total current liabilities	238,859	213,435
Long-term lease liability	165,075	134,810
Long-term equipment financing liability	1,388	3,007
Contingent consideration liabilities	31,910	31,367
Long-term portion of deferred revenue	198,288	262,303
Other liabilities	253	2,793
Total liabilities	635,773	647,715
Commitments and contingencies (See Note 7, Leases, Note 10, License agreements and Note 11, Collaboration and license agreements)
Stockholders’ equity:
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at September 30, 2022 and December 31, 2021, respectively
Common stock, $0.01 par value; 250,000,000 shares authorized, 70,468,614 and 68,581,251 issued, and 70,457,676 and 68,389,425 outstanding at September 30, 2022 and December 31, 2021, respectively	705	684
Additional paid-in capital	1,737,459	1,594,378
Accumulated other comprehensive (loss) income	(4,674)	(50)
Accumulated deficit	(1,019,013)	(768,274)
Total stockholders’ equity	714,477	826,738
Total liabilities and stockholders equity	$ 1,350,250	$ 1,474,453

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par or stated value per share	$ 0.01	$ 0.01
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par or stated value per share	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	70,468,614	68,581,251
Common stock, shares outstanding	70,457,676	68,389,425

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
License and collaboration revenue	$ 15,799	$ 763	$ 40,883	$ 775
Revenue, Product and Service [Extensible List]	us-gaap:LicenseMember	us-gaap:LicenseMember	us-gaap:LicenseMember	us-gaap:LicenseMember
Operating expenses:
Research and development	$ 85,287	$ 54,623	$ 225,253	$ 290,306
General and administrative	21,815	15,774	65,124	39,450
Total operating expenses	107,102	70,397	290,377	329,756
Loss from operations	(91,303)	(69,634)	(249,494)	(328,981)
Other income (expense):
Change in fair value of derivative liabilities	(4,900)	35,800	20,900	(8,400)
Change in fair value of non-controlling equity investments	10,431	(4,892)	(1,378)	21,960
Change in fair value of contingent consideration liabilities	(875)	10,599	(543)	9,553
Interest and other income (expense), net	4,982	9	7,686	(63)
Total other income (expense)	9,638	41,516	26,665	23,050
Net loss before income taxes	(81,665)	(28,118)	(222,829)	(305,931)
Provision for income taxes	(2,410)	0	(2,410)	0
Loss from equity method investment	(25,500)		(25,500)
Net loss	(109,575)	(28,118)	(250,739)	(305,931)
Unrealized gain (loss) on marketable securities	(484)	(12)	(4,624)	28
Comprehensive loss	$ (110,059)	$ (28,130)	$ (255,363)	$ (305,903)
Net loss per common share, basic	$ (1.56)	$ (0.42)	$ (3.59)	$ (4.86)
Net loss per common share, diluted	$ (1.56)	$ (0.42)	$ (3.59)	$ (4.86)
Weighted-average common shares outstanding, basic	70,343,196	66,377,611	69,758,434	62,960,219
Weighted-average common shares outstanding, diluted	70,343,196	66,377,611	69,758,434	62,960,219

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning Balance at Dec. 31, 2020	$ 245,561	$ 573	$ 642,633	$ (9)	$ (397,636)
Beginning Balance, Shares at Dec. 31, 2020		57,254,178
Issuance of common stock from private placement/At-the-Market offering, net of issuance costs	252,005	$ 28	251,977
Issuance of common stock from private placement/At-the-Market offering, net of issuance costs, Shares		2,795,700
Issuance of common stock to acquire Guide	120,032	$ 10	120,022
Issuance of common stock to acquire Guide, Shares		1,087,153
Vesting of restricted common stock		$ 4	(4)
Vesting of restricted common stock, Shares		398,804
Stock-based compensation	4,648		4,648
Exercise of common stock options	1,758	$ 2	1,756
Exercise of common stock options, Shares		199,284
Other comprehensive income (loss)	(15)			(15)
Net loss	(201,560)				(201,560)
Ending Balance at Mar. 31, 2021	422,429	$ 617	1,021,032	(24)	(599,196)
Ending Balance, Shares at Mar. 31, 2021		61,735,119
Beginning Balance at Dec. 31, 2020	245,561	$ 573	642,633	(9)	(397,636)
Beginning Balance, Shares at Dec. 31, 2020		57,254,178
Net loss	(305,931)
Ending Balance at Sep. 30, 2021	853,814	$ 677	1,556,685	19	(703,567)
Ending Balance, Shares at Sep. 30, 2021		67,734,484
Beginning Balance at Mar. 31, 2021	422,429	$ 617	1,021,032	(24)	(599,196)
Beginning Balance, Shares at Mar. 31, 2021		61,735,119
Issuance of common stock from private placement/At-the-Market offering, net of issuance costs	157,785	$ 18	157,767
Issuance of common stock from private placement/At-the-Market offering, net of issuance costs, Shares		1,761,285
Vesting of restricted common stock		$ 2	(2)
Vesting of restricted common stock, Shares		200,403
Issuance of common stock for success payment liability	30,000	$ 4	29,996
Issuance of common stock for success payment liability, Shares		349,650
Stock-based compensation	10,452		10,452
Exercise of common stock options	4,083	$ 4	4,079
Exercise of common stock options, Shares		406,225
Other comprehensive income (loss)	55			55
Net loss	(76,253)				(76,253)
Ending Balance at Jun. 30, 2021	548,551	$ 645	1,223,324	31	(675,449)
Ending Balance, Shares at Jun. 30, 2021		64,452,682
Issuance of common stock from private placement/At-the-Market offering, net of issuance costs	318,609	$ 29	318,580
Issuance of common stock from private placement/At-the-Market offering, net of issuance costs, Shares		2,912,557
Vesting of restricted common stock		$ 2	(2)
Vesting of restricted common stock, Shares		200,402
Stock-based compensation	12,968		12,968
Exercise of common stock options	1,816	$ 1	1,815
Exercise of common stock options, Shares		168,843
Other comprehensive income (loss)	(12)			(12)
Net loss	(28,118)				(28,118)
Ending Balance at Sep. 30, 2021	853,814	$ 677	1,556,685	19	(703,567)
Ending Balance, Shares at Sep. 30, 2021		67,734,484
Beginning Balance at Dec. 31, 2021	826,738	$ 684	1,594,378	(50)	(768,274)
Beginning Balance, Shares at Dec. 31, 2021		68,389,425
Purchase of common stock under ESPP	1,412		1,412
Purchase of common stock under ESPP, Shares		28,990
Issuance of common stock from private placement/At-the-Market offering, net of issuance costs	53,936	$ 9	53,927
Issuance of common stock from private placement/At-the-Market offering, net of issuance costs, Shares		874,770
Vesting of restricted common stock		$ 3	(3)
Vesting of restricted common stock, Shares		283,186
Stock-based compensation	18,035		18,035
Exercise of common stock options	820	$ 2	818
Exercise of common stock options, Shares		176,652
Other comprehensive income (loss)	(2,659)			(2,659)
Net loss	(69,214)				(69,214)
Ending Balance at Mar. 31, 2022	829,068	$ 698	1,668,567	(2,709)	(837,488)
Ending Balance, Shares at Mar. 31, 2022		69,753,023
Beginning Balance at Dec. 31, 2021	$ 826,738	$ 684	1,594,378	(50)	(768,274)
Beginning Balance, Shares at Dec. 31, 2021		68,389,425
Exercise of common stock options, Shares	369,444
Net loss	$ (250,739)
Ending Balance at Sep. 30, 2022	714,477	$ 705	1,737,459	(4,674)	(1,019,013)
Ending Balance, Shares at Sep. 30, 2022		70,457,676
Beginning Balance at Mar. 31, 2022	829,068	$ 698	1,668,567	(2,709)	(837,488)
Beginning Balance, Shares at Mar. 31, 2022		69,753,023
Issuance of common stock from private placement/At-the-Market offering, net of issuance costs	22,300	$ 4	22,296
Issuance of common stock from private placement/At-the-Market offering, net of issuance costs, Shares		374,677
Vesting of restricted common stock, Shares		37,118
Stock-based compensation	21,578		21,578
Exercise of common stock options	646	$ 1	645
Exercise of common stock options, Shares		147,296
Other comprehensive income (loss)	(1,481)			(1,481)
Net loss	(71,950)				(71,950)
Ending Balance at Jun. 30, 2022	800,161	$ 703	1,713,086	(4,190)	(909,438)
Ending Balance, Shares at Jun. 30, 2022		70,312,114
Purchase of common stock under ESPP	1,664		1,664
Purchase of common stock under ESPP, Shares		41,083
Vesting of restricted common stock		$ 1	(1)
Vesting of restricted common stock, Shares		58,983
Stock-based compensation	22,209		22,209
Exercise of common stock options	502	$ 1	501
Exercise of common stock options, Shares		45,496
Other comprehensive income (loss)	(484)			(484)
Net loss	(109,575)				(109,575)
Ending Balance at Sep. 30, 2022	$ 714,477	$ 705	$ 1,737,459	$ (4,674)	$ (1,019,013)
Ending Balance, Shares at Sep. 30, 2022		70,457,676

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021
Private Placement
Stock issuance costs					$ 8
ATM Offering
Stock issuance costs	$ 0.6	$ 1.3	$ 8.6	$ 5.5

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities
Net loss	$ (250,739)	$ (305,931)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Loss from equity method investment	25,500
Depreciation and amortization	10,203	4,817
Amortization of investment discount (premiums)	(4,308)	(28)
In-process research and development charge		154,953
Stock-based compensation expense	61,822	28,068
Change in operating lease right-of-use assets	6,237	6,781
Change in fair value of derivative liabilities	(20,900)	8,400
Change in fair value of contingent consideration liabilities	543	(9,553)
Change in fair value of non-controlling equity investments	1,378	(21,960)
Other	3	63
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(7,192)	733
Other long-term assets		(197)
Accounts payable	(527)	(1,341)
Accrued expenses and other liabilities	(25,376)	2,818
Operating lease liabilities	13,496	15,208
Collaboration receivable	300,000
Deferred revenue	(15,883)	49,224
Other long-term liabilities	(2,539)	(153)
Net cash provided by (used in) operating activities	91,718	(68,098)
Investing activities
Purchases of property and equipment	(40,690)	(33,442)
Purchases of marketable securities	(1,378,609)	(606,746)
Maturities of marketable securities	844,524	422,920
Net cash acquired from Guide		620
Net cash used in investing activities	(574,775)	(216,648)
Financing activities
Proceeds from issuance of common shares, net of commissions	76,365	737,205
Proceeds from issuances of stock under ESPP	3,076
Payment of equity offering costs	(134)	(8,688)
Repayment of equipment financings	(1,697)	(1,576)
Proceeds from exercise of stock options	1,968	7,657
Net cash provided by financing activities	79,578	734,598
Net change in cash, cash equivalents and restricted cash	(403,479)	449,852
Cash, cash equivalents and restricted cash—beginning of period	572,740	177,011
Cash, cash equivalents and restricted cash—end of period	169,261	626,863
Supplemental disclosure of cash flow information:
Cash paid for interest	300	443
Supplemental disclosure of noncash investing and financing activities:
Property and equipment additions in accounts payable and accrued expenses	5,658	7,515
Operating lease liabilities arising from obtaining right-of-use assets	35,877	24,164
Non-cash contribution of intellectual property to Orbital Therapeutics Inc.	$ 25,500
Fair value of common stock issued to settle success payment liability		30,000
Equity issuance costs in accounts payable and accrued expenses		118
Contingent consideration liabilities assumed in asset acquisition		36,513
Fair value of equity instruments issued in connection with asset acquisition		$ 120,032

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business and Basis of Presentation	1. Nature of the business and basis of presentation Organization Beam Therapeutics Inc., which we refer to herein as the “Company” or “Beam,” is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Beam’s vision is to provide life-long cures to patients suffering from genetic diseases. The Company was incorporated on January 25, 2017 as a Delaware corporation and began operations in July 2017. Its principal offices are in Cambridge, Massachusetts. Liquidity and capital resources Since its inception, the Company has devoted substantially all of its resources to building its base editing platform and advancing development of its portfolio of programs, establishing and protecting its intellectual property, conducting research and development activities, making arrangements to conduct manufacturing activities with contract manufacturing organizations, research and development costs including preclinical studies and IND-enabling studies, organizing and staffing the Company, maintaining its facilities and new facility build-outs, business planning, raising capital and providing general and administrative support for these operations. The Company is also in the process of developing internal manufacturing capabilities. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. In April 2021, the Company entered into an at the market, or ATM, sales agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, pursuant to which the Company was entitled to offer and sell, from time to time at prevailing market prices, shares of the Company’s common stock having aggregate gross proceeds of up to $ 300.0 million. The Company agreed to pay Jefferies a commission of up to 3.0 % of the aggregate gross sale proceeds of any shares sold by Jefferies under the Sales Agreement. Between April and July 2021, the Company sold 2,908,009 shares of its common stock under the Sales Agreement at an average price of $ 103.16 per share for aggregate gross proceeds of $ 300.0 million, before deducting commissions and offering expenses payable by the Company. In July 2021, the Company and Jefferies entered into an amendment to the Sales Agreement to provide for an increase in the aggregate offering amount under the Sales Agr eement, such that as of July 7, 2021, the Company may offer and sell shares of common stock having an aggregate offering price of an additional $ 500.0 million. As of September 30, 2022, the Company has sold 3,248,633 additional shares of its common stock under the amended Sales Agreement at an average price of $ 89.06 per share for aggregate gross proceeds of $ 289.3 million, before deducting commissions and offering expenses payable by the Company. Since its inception, the Company has incurred substantial losses and had an accumulated deficit of $ 1.0 billion as of September 30, 2022. The Company expects to generate operating losses and negative operating cash flows for the foreseeable future. The Company expects that its cash, cash equivalents, and marketable securities as of September 30, 2022 of $ 1.1 billion will be sufficient to fund its operations for at least the next 12 months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed would have a negative impact on the Company’s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so. COVID-19-related significant risks and uncertainties With the ongoing concerns related to the COVID-19 pandemic, the Company has maintained its business continuity plans to address and mitigate the impact of the COVID-19 pandemic on its business. In March 2020, to protect the health of its employees, and their families and communities, the Company restricted access to its offices to personnel who performed critical activities that must be completed on-site, limited the number of such personnel that could be present at its facilities at any one time, and requested that most of its employees work remotely. In May 2021, as certain states eased restrictions, the Company established new protocols to better allow its full laboratory staff access to the Company’s facilities. These protocols included several shifts working over a seven-day-week protocol. In June 2021, as certain states continued to ease restrictions, the Company started to allow its entire workforce the ability to work on-site at the Company’s facilities, with fewer restrictions, particularly for vaccinated employees. The Company expects to continue incurring additional costs to ensure it adheres to the guidelines instituted by the Centers for Disease Control and Prevention and to provide a safe working environment to its onsite employees. The extent to which the COVID-19 pandemic impacts the Company’s business, its corporate development objectives, results of operations and financial condition, and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements, and the effectiveness of actions taken globally to contain and treat the disease. Disruptions to the global economy and supply chain, disruption of global healthcare systems, and other significant impacts of the COVID-19 pandemic could have a material adverse effect on the Company’s business, financial condition, results of operations and growth prospects. While the COVID-19 pandemic did not significantly impact the Company’s business or results of operations during the three or nine months ended September 30, 2022 , the length and extent of the pandemic, its consequences, and containment efforts will determine the future impact on the Company’s operations and financial condition.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. S ummary of significant accounting policies The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2021, and notes thereto, which are included in the Company’s Annual Report on Form 10-K that was filed with the Securities and Exchange Commission, or the SEC, on February 28, 2022, or the 2021 Form 10-K. Since the date of those financial statements, there have been no material changes to Beam’s significant accounting policies except with respect to equity method accounting as described below. Basis of presentation The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board. Principles of consolidation The accompanying condensed consolidated financial statements include the results of operations of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, incremental borrowing rate used in the calculation of lease liabilities, research and development expenses, stock-based compensation, contingent consideration liabilities, success payments and certain judgements regarding revenue recognition. Actual results could differ from these estimates. Cash, cash equivalents, and restricted cash Cash and cash equivalents consist of standard checking accounts, money market accounts, and all highly liquid investments with a remaining maturity of three months or less at the date of purchase. Restricted cash represents collateral provided for letters of credit issued as security deposits in connection with the Company’s leases of its corporate and manufacturing facilities. The following table reconciles cash, cash equivalents, and restricted cash reported within the Company’s condensed consolidated balance sheets to the total of the amounts shown in the condensed consolidated statements of cash flows (in thousands): September 30, September 30, Cash and cash equivalents $ 156,511 $ 612,023 Restricted cash 12,750 14,840 Total cash, cash equivalents, and restricted cash $ 169,261 $ 626,863 Equity method of accounting In circumstances where the Company has the ability to exercise significant influence, but not control, over the operating and financial policies of an entity in which the Company has an investment in common stock or in-substance common stock, the Company utilizes the equity method of accounting for recording related investment activity. In assessing whether the Company exercises significant influence, the Company considers the nature and magnitude of the investment, participating rights the Company holds, and relevant factors such as the presence of a collaborative or other business relationship. Under the equity method of accounting, the Company’s investments are initially recorded at cost on the consolidated balance sheets. Upon recording an equity method investment, the Company evaluates whether there are basis differences between the carrying value and fair value of the Company’s proportionate share of the investee’s underlying net assets. Typically, the Company amortizes basis differences identified on a straight-line basis over the underlying asset’s or liability's estimated useful lives when calculating the attributable earnings or losses, excluding the basis differences attributable to in-process research and development, or IPR&D, that has no alternative future use. To the extent a basis difference relates to IPR&D and the investee is not a business as defined in ASC 805, the Company immediately expenses such basis difference related to IPR&D. If the Company is unable to attribute all of the basis difference to specific assets or liabilities of the investee, the residual excess of the cost of the investment over the proportional fair value of the investee’s assets and liabilities is considered to be Equity Method Goodwill and is recognized within the equity investment balance, which is tracked separately within the Company’s memo accounts. The Company subsequently records in the consolidated statements of operations and comprehensive loss its share of income or loss of the other entity within the loss from equity method investment line item. If the share of losses exceeds the carrying value of the Company’s investment, the Company will suspend recognizing additional losses and will continue to do so unless it commits to providing additional funding. The Company evaluates its equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amounts of such investments may be impaired and considers qualitative and quantitative factors including the investee’s financial metrics, product and commercial outlook and cash usage. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period and the investment is written down to fair value. At September 30, 2022 , the Company accounted for its investment in Orbital Therapeutics, Inc., or Orbital, under the equity method of accounting. Refer to Note 8 for further details.

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	3. P roperty and equipment, net Property and equipment consist of the following (in thousands): September 30, December 31, Leasehold improvements $ 58,151 $ 57,760 Lab equipment 40,531 29,905 Furniture and fixtures 3,738 3,679 Computer equipment 1,925 1,646 Construction in process 33,061 7,349 Total property and equipment 137,406 100,339 Less accumulated depreciation ( 26,226 ) ( 16,081 ) Property and equipment, net $ 111,180 $ 84,258 The following table summarizes depreciation expense incurred (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Depreciation expense $ 3,473 $ 1,675 $ 10,153 $ 4,642

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	4. f air value of financial instruments The Company’s financial instruments that are measured at fair value on a recurring basis consist of cash equivalents, marketable securities, equity securities of Verve Therapeutics, Inc, or Verve, contingent consideration liabilities related to the agreement and plan of merger pursuant to which the Company acquired Guide, or the Guide Merger Agreement, and success payment derivative liabilities pursuant to the license agreement, or the Harvard License Agreement, between President and Fellows of Harvard University, or Harvard, and the Company, and the license agreement, or the Broad License Agreement, between The Broad Institute, Inc., or Broad Institute, and the Company. The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy at September 30, 2022 (in thousands): Carrying Fair Level 1 Level 2 Level 3 Assets Cash equivalents: Money market funds $ 124,096 124,096 $ 124,096 $ — $ — Commercial paper 32,415 32,415 — 32,415 — Marketable securities: Commercial paper 621,335 621,335 — 621,335 — Corporate notes 18,921 18,921 — 18,921 — U.S. Treasury securities 224,320 224,320 — 224,320 — U.S Government securities 54,679 54,679 — 54,679 — Equity securities included in marketable securities: Corporate equity securities 18,788 18,788 18,788 — — Total assets $ 1,094,554 $ 1,094,554 $ 142,884 $ 951,670 $ — Liabilities Success payment liability – Harvard $ 10,500 $ 10,500 $ — $ — $ 10,500 Success payment liability – Broad Institute 10,800 10,800 — — 10,800 Contingent consideration liability – Technology 25,835 25,835 — — 25,835 Contingent consideration liability – Product 6,075 6,075 — — 6,075 Total liabilities $ 53,210 $ 53,210 $ — $ — $ 53,210 The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy at December 31, 2021 (in thousands): Carrying Fair Level 1 Level 2 Level 3 Assets Cash equivalents: Money market funds $ 540,094 $ 540,094 $ 540,094 $ — $ — Commercial paper 13,997 13,997 — 13,997 — Corporate notes 5,903 5,903 — 5,903 — Marketable securities: Commercial paper 368,743 368,743 — 368,743 — Corporate notes 16,743 16,743 — 16,743 — Equity securities included in marketable securities: Corporate equity securities 20,167 20,167 20,167 — — Total assets $ 965,647 $ 965,647 $ 560,261 $ 405,386 $ — Liabilities Success payment liability – Harvard $ 21,000 $ 21,000 $ — $ — $ 21,000 Success payment liability – Broad Institute 21,200 21,200 — — 21,200 Contingent consideration liability – Technology 24,359 $ 24,359 — — 24,359 Contingent consideration liability – Product 7,008 7,008 — — 7,008 Total liabilities $ 73,567 $ 73,567 $ — $ — $ 73,567 Cash equivalents – Money market funds included within cash equivalents are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. Commercial paper and corporate notes are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies. Marketable securities – Marketable securities, excluding corporate equity securities, are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined using models or other valuation methodologies. The Company holds an investment in Verve consisting of shares of Verve’s common stock. Prior to Verve's initial public offering in June 2021, the Company valued such investment based on the cost of the equity securities adjusted for any observable market transactions. Following Verve's initial public offering, the equity securities have a readily determinable fair value. As of September 30, 2022, the Company owned 546,970 shares of Verve's common stock valued at $ 18.8 million, which is included in marketable securities in the condensed consolidated balance sheet. The following table summarizes other income (expense) incurred due to changes in the fair value of corporate equity securities held (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Other income (expense) $ 10,431 $ ( 4,892 ) $ ( 1,378 ) $ 21,960 Pursuant to ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities , the Company records changes in the fair value of its investments in equity securities to other income (expense), in the Company’s condensed consolidated statements of operations. Success payment liabilities – As discussed further in Note 10, License agreements , the Company is required to make payments to Harvard and Broad Institute based upon the achievement of specified multiples of the initial weighted average value of the Company’s Series A Preferred Stock or, subsequent to the Company’s initial public offering, or IPO, the market value of the Company's common stock, at specified valuation dates. The Company’s liability for the share-based success payments under the Harvard and Broad License Agreements is carried at fair value. To determine the estimated fair value of the success payment liability, the Company uses a Monte Carlo simulation methodology, which models the future movement of stock prices based on several key variables. The following variables were incorporated in the calculation of the estimated fair value of the Harvard and Broad Institute success payment liabilities: Harvard Broad Institute September 30, December 31, September 30, December 31, Fair value of common stock (per share) $ 47.64 $ 79.69 $ 47.64 $ 79.69 Expected volatility 82 % 76 % 82 % 76 % Expected term (years) 0.09 - 6.75 0.10 - 7.49 0.09 - 7.61 0.10 - 8.36 The computation of expected volatility was estimated using available information about the historical volatility of stocks of similar publicly traded companies in addition to the Company's own data for a period matching the expected term assumption. In addition, the Company incorporated the estimated number, timing, and probability of valuation measurement dates in the calculation of the success payment liability. The following table reconciles the change in the fair value of success payment liabilities based on Level 3 inputs (in thousands): Nine Months Ended September 30, 2022 Harvard Broad Institute Total Balance at December 31, 2021 $ 21,000 $ 21,200 $ 42,200 Change in fair value ( 10,500 ) ( 10,400 ) ( 20,900 ) Balance at September 30, 2022 $ 10,500 $ 10,800 $ 21,300 Contingent consideration liabilities – As discussed further in Note 9, Guide acquisition , under the Guide Merger Agreement, Guide’s former stockholders and optionholders are eligible to receive up to an additional $ 100.0 million in technology milestone payments and $ 220.0 million in product milestone payments, payable in the Company’s common stock valued using the volume-weighted average price of the Company’s stock over the ten-day trading period ending two trading days prior to the date on which the applicable milestone is achieved. As these milestones are payable in the Company’s common stock, the milestone payments result in liability classification under ASC 480, Distinguishing Liabilities from Equity . These contingent consideration liabilities are carried at fair value which was estimated by applying a probability-based model, which utilized inputs based on timing of achievement that were unobservable in the market. These contingent consideration liabilities are classified within Level 3 of the fair value hierarchy. The following table reconciles the change in fair value of the contingent consideration liabilities based on level 3 inputs (in thousands): Nine Months Ended September 30, 2022 Technology Milestones Product Milestones Total Balance at December 31, 2021 $ 24,359 $ 7,008 $ 31,367 Change in fair value 1,476 ( 933 ) 543 Balance at September 30, 2022 $ 25,835 $ 6,075 $ 31,910 The following variables were incorporated in the calculation of the estimated fair value of the contingent consideration liabilities: Technology Milestones Product Milestones September 30, December 31, September 30, December 31, Discount Rate 10.50 % 7.50 % 10.50 % 7.50 % Probability of Achievement 10 - 90 % 10 - 75 % 2 - 15 % 2 - 15 % Projected Year of Achievement 2022 - 2024 2022 - 2023 2024 - 2029 2023 - 2029

Marketable Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	5. Marketable securities The following table summarizes the Company’s marketable securities held at September 30, 2022 (in thousands): Amortized Cost Gross Gross Fair Value Commercial paper $ 623,804 $ 2 $ ( 2,471 ) $ 621,335 Corporate notes 19,093 — ( 172 ) 18,921 U.S. Treasury securities 226,112 — ( 1,792 ) 224,320 U.S. Government securities 54,920 — ( 241 ) 54,679 Corporate equity securities 18,788 — — 18,788 Total $ 942,717 $ 2 $ ( 4,676 ) $ 938,043 The following table summarizes the Company’s marketable securities held at December 31, 2021 (in thousands): Amortized Cost Gross Gross Fair Value Commercial paper $ 368,778 $ 32 $ ( 67 ) $ 368,743 Corporate notes 16,758 — ( 15 ) 16,743 Corporate equity securities 20,167 — — 20,167 Total $ 405,703 $ 32 $ ( 82 ) $ 405,653 The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity. At September 30, 2022 , the balance in accumulated other comprehensive (loss) income was comprised solely of activity related to marketable securities. There were no realized gains or losses recognized on the sale or maturity of marketable securities for the three or nine months ended September 30, 2022 and 2021 and, as a result, the Company did not reclassify any amounts out of accumulated other comprehensive (loss) income for the same periods. The Company holds debt securities of companies with high credit quality and has determined that there was no material change in the credit risk of any of its debt securities. The contractual maturity dates of all the investments are less than one year .

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	6. Accrued expenses and other current liabilities Accrued expenses and other current liabilities consist of the following (in thousands): September 30, December 31, Employee compensation and related benefits $ 12,004 $ 11,661 Research costs 5,363 3,133 Professional fees 3,543 3,330 Process development and manufacturing costs 4,601 3,833 Other 13,089 6,964 Total $ 38,600 $ 28,921 The Company recently received correspondence from a research institution regarding a confidentiality agreement between such institution and the Company. The confidentiality agreement related to certain technology that the Company evaluated for development in connection with certain of its programs. The correspondence alleges that the Company breached the terms of the confidentiality agreement, misappropriated trade secret and other confidential information of such institution, engaged in unfair and deceptive trade practices, and was unjustly enriched in connection with developing its therapeutics, including BEAM-102 and the Company’s Alpha-1 Antitrypsin Deficiency therapeutic candidate (which the Company now refers to as BEAM-302). The research institution claims that it is entitled to monetary damages (including damages for the apportioned value of the Company and enhanced damages for an alleged willful violation) and certain ongoing royalty and/or milestone payments related to the technology that is the subject of the alleged breaches of contract, among other possible remedies. As of September 30, 2022, the Company has accrued a $ 3.4 million liability equal to an amount the Company offered to resolve the dispute. The settlement proposal was rejected by the research institution. No complaint has been filed, and the Company continues to discuss the matter with the research institution. Although it may do so, the Company has not determined to make a further offer and believes that it is unable at this time to provide any estimate of a reasonably possible loss in excess of the amount offered. The ultimate resolution of this matter could result in an outcome that is materially different from the amount accrued as of September 30, 2022.

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Leases	7. Leases Operating leases The Company’s operating leases are as follows: • A February 2018 lease for 38,203 square feet of office and laboratory space, which commenced in March 2018 and terminates in September 2028 . The lease is subject to fixed-rate rent escalations and provided for $ 6.1 million in tenant improvements and a term extension option , which is not reasonably certain of exercise. • An October 2018 lease for laboratory space as amended, which commenced in April 2019 and terminates in December 2025 . The amended lease is subject to fixed-rate rent escalations and provides an option to extend the lease for two additional two-year periods through December 31, 2029, which are not reasonably certain of being exercised. Through September 30, 2022 , the Company has recorded ROU assets and lease liabilities of $ 14.1 million and $ 14.0 million related to this lease. • An April 2019 lease for office and laboratory space that was built over the course of 2020 and 2021. Pursuant to the terms of the original lease agreement, the first phase of the lease commenced in October 2020 (rent payments for the first phase began in August 2021 ) and the second phase of the lease commenced in January 2021 (rent payments for the second phase began in February 2022 ). The lease is subject to fixed-rate rent escalations and provides for $ 23.4 million in tenant improvements and the option to extend the lease for two terms of five years each, which are not reasonably certain of exercise. The Company determined that it is the accounting owner of all tenant improvements. The Company maintains a security deposit of $ 9.7 million in the form of a letter of credit, which is included in restricted cash as of September 30, 2022 and December 31, 2021 . Upon commencement of the first phase of this lease in October 2020, the Company recorded an operating lease ROU asset of $ 66.8 million and a lease liability of $ 68.8 million and upon commencement of the second phase of this lease in January 2021, the Company recorded an operating lease ROU asset of $ 22.0 million and a corresponding lease liability of $ 23.0 million. Subsequently, during the second quarter of 2021, the Company amended the rent commencement dates of the first and second phases of this lease. Pursuant to the terms of the amendment, the lease will terminate in February 2034 , which is 12 years from the amended second phase rent commencement date. As a result, the Company recorded an increase in the ROU asset of $ 0.5 million and lease liability of $ 0.5 million. • An August 2020 lease for a 100,000 square foot manufacturing facility in Research Triangle Park, North Carolina. Construction of the manufacturing facility began in 2020 and the Company expects to begin making rent payments in the first quarter of 2023. The lease will terminate 15 years from the rent commencement date. The lease is subject to fixed-rate rent escalations and provides for $ 20.0 million in tenant improvements and the option to extend the lease for two terms of five years each, which were not reasonably certain of exercise as of September 30, 2022 . The Company determined that it is the accounting owner of all tenant improvements under the lease. Upon executing the lease in August 2020, the Company made a security deposit of $ 1.5 million in the form of a letter of credit, which is included in restricted cash as of September 30, 2022 and December 31, 2021. Upon commencement of this lease in June 2022 , the Company recorded an operating lease ROU asset of $ 13.6 million and a lease liability of $ 30.4 million. The variance between the ROU asset and lease liability recorded relates to $ 16.8 million of tenant improvement allowance completed through the lease commencement date. The $ 16.8 million of tenant improvement allowance is presented as an operating cash inflow and investing cash outflow within the Company’s condensed consolidated statements of cash flows. The rent payments are subject to adjustment following the determination of the total project costs of the landlord and represent in substance fixed payments that are included in the total future minimum lease payments. The following table summarizes operating lease costs and sublease income (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Operating lease costs $ 5,306 $ 4,557 $ 14,161 $ 13,660 Variable lease costs 643 588 3,310 1,162 Short-term lease costs 38 383 308 761 Sublease income ( 331 ) — ( 993 ) — Total $ 5,656 $ 5,528 $ 16,786 $ 15,583 The following table summarizes the lease term and discount rate for operating leases: September 30, December 31, Weighted-average remaining lease term (years) 11.2 11.1 Weighted-average discount rate 7.5 % 7.0 % The following table summarizes the lease costs for amounts included in the measurement of lease liabilities (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Operating cash flows used for operating leases $ 4,603 $ 3,058 $ 14,057 $ 7,053 Operating lease liabilities arising from obtaining ROU assets 250 — 35,877 24,164 At September 30, 2022, the future minimum lease payments for the Company’s operating leases for each of the next five years and total thereafter were as follows (in thousands): Remainder of 2022 $ 4,687 2023 22,629 2024 23,614 2025 24,179 2026 21,344 Thereafter 168,733 Undiscounted lease payments 265,186 Less: imputed interest ( 90,288 ) Total operating lease liabilities $ 174,898 In August 2021, the Company executed a lease amendment to its April 2019 lease for office and laboratory space in Cambridge, Massachusetts to occupy additional space. The term of this lease will run concurrent with the term of the April 2019 lease. The initial estimate of the minimum amount of undiscounted lease payments due under this lease is $ 11.1 million. As the lease had not yet commenced as of September 30, 2022 , the Company has not recorded an operating lease ROU asset or lease liability for this lease in the accompanying condensed consolidated balance sheets. The tabular disclosure of minimum lease payments above does not include payments due under this lease.

Equity Method Investment

Equity Method Investment	9 Months Ended
	Sep. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investment	8. Equity method investment Orbital In September 2022, the Company entered into a License and Research Collaboration Agreement, or the Orbital Agreement, with Orbital Therapeutics, Inc., or Orbital, a newly formed entity, focused on advancing non-viral delivery and RNA technologies (See Note 11). In exchange for contributing exclusive and non-exclusive licenses and certain services, the Company received a 31.5 % fully diluted equity interest in Orbital at the time of closing pursuant to a Common Stock Issuance Agreement, or the Orbital Issuance Agreement, as well as certain exclusive and non-exclusive licenses from Orbital. As of the closing date Beam held 97.0 % of the outstanding common stock of Orbital. Additionally, certain members of the Company's executive team are providing interim management services to Orbital under separate agreements between Orbital and the executives. Orbital is not compensating the Company for the interim management services. The Company has significant influence over, but does not control, Orbital through its noncontrolling representation on Orbital’s board of directors and the Company’s equity interest in Orbital. The Company determined that Orbital is a variable interest entity because it does not have sufficient equity at risk to finance its operations without additional subordinated financial support. The Company is not the primary beneficiary as it does not have the power to direct activities that most significantly impact Orbital’s economic performance. Accordingly, the Company does not consolidate the financial statements of Orbital and accounts for its investment using the equity method of accounting. As of the closing date, the fair value of the Company’s investment in Orbital was $ 25.5 million, which represents the fair value of the common stock received under the Orbital Issuance Agreement (See Note 11). The fair value of the Orbital common stock was determined by management with the assistance of a third-party valuation specialist. In determining the fair value of the Company’s investment, the valuation specialist used an option pricing model backsolve approach b ased on Orbital's most recent funding of preferred stock. The valuation requires the input of certain subjective assumptions. The key assumptions used in the option pricing model, which are level 3 inputs, include the anticipated holding period to an exit and liquidity event, the volatility of market participants ( 68 %) and the discount for lack of marketability ( 43 %). After its initial investment, the Company will adjust the carrying value of its investment in Orbital by its proportionate share of Orbital’s net loss based on the Company’s share, of Orbital’s outstanding common stock and in-substance common stock. At the date of the investment, a basis difference was identified as the carrying value of the Company’s investment in Orbital exceeded the Company’s proportionate share of the underlying net assets in Orbital. The Company concluded that the basis difference was primarily attributable to Orbital’s IPR&D assets. As Orbital did not meet the definition of a business due to substantially all of the estimated fair value of the gross assets being concentrated in the group of similar IPR&D assets, the basis difference attributable to the IPR&D with no alternative future use was immediately expensed as of the date of the investment. The Company’s proportionate share of the basis difference exceeded its carrying value of the equity method investment in Orbital and the equity investment balance was reduced to zero . There is no commitment for the Company to provide financial support to Orbital, and therefore the carrying value of the equity method investment will not be reduced below zero. For the three and nine months ended September 30, 2022 , the Company recognized a loss from its equity method investment of $ 25.5 million in association with the basis difference charge in the Company’s condensed consolidated statements of operations. The maximum exposure to loss is limited to the Company’s equity investment in Orbital, which has a carrying value of zero at September 30, 2022 . To date the Company has no t received any dividends from Orbital.

Guide Acquisition

Guide Acquisition	9 Months Ended
	Sep. 30, 2022
Business Combinations [Abstract]
Guide Acquisition	. Guide acquisition On February 23, 2021 , the Company entered into the Guide Merger Agreement. Under the Guide Merger Agreement, the Company paid Guide’s former stockholders and optionholders upfront consideration in an aggregate amount of $ 120.0 million, excluding customary purchase price adjustments and closing costs, in shares of the Company’s common stock, based upon the volume-weighted average price of the Company’s stock over the ten trading day period ending on February 19, 2021. Pursuant to the Guide Merger Agreement, the Company acquired all of the issued and outstanding shares of Guide. The Company issued a total of 1,087,153 shares of its common stock valued at $ 120.0 million in connection with the upfront payment to Guide’s former stockholders and optionholders. The Guide transaction resulted in the acquisition of certain know-how and intellectual property assets related to Guide’s proprietary in vivo LNP screening technology and its library of lipids and lipid nanoparticle formulations identified using the screening technology. Management determined that the acquired assets do not meet the definition of a business pursuant to ASC 805, Business Combinations , as substantially all of the fair value of the acquired assets is concentrated into one identifiable asset, the LNP screening technology and associated lipid library. As of the date of closing of the transactions contemplated by the Guide Merger Agreement, or the Guide Merger Agreement Date, the asset acquired had no alternative future use and had not reached a stage of technological feasibility. As a result, all share-based and cash payment obligations have been recorded as research and development expense in the accompanying condensed consolidated statements of operations and other comprehensive loss in the amount of $ 155.0 million. The total transaction price was allocated to the assets acquired and liabilities assumed on a relative fair value basis. In addition, Guide’s former stockholders and optionholders are eligible to receive up to an additional $ 100.0 million in technology milestone payments and $ 220.0 million in product milestone payments, payable in the Company’s common stock valued using the volume-weighted average price of the Company’s stock over the ten trading-day period ending two trading days prior to the date on which the applicable milestone is achieved. The Company determined that all future technology and product milestone payments are classified as contingent consideration liabilities under ASC 480 and therefore the Company recorded a liability for these milestone payments as of the Guide Merger Agreement Date at fair value of $ 36.5 million. These contingent consideration liabilities are remeasured at fair value each financial reporting period, with the resulting impact reflected in the Company’s condensed consolidated statements of operations and other comprehensive loss, presented within other income (expense). The transaction price was determined and allocated as follows (in thousands): Transaction price Fair value of equity instruments issued $ 120,032 Technology and product contingent consideration liabilities 36,513 Transaction costs 2,531 Total transaction price $ 159,076 Transaction price allocated In-process research and development $ 154,953 Cash acquired 3,151 Prepaid expenses and other assets 264 Property and equipment 1,835 Assembled workforce 300 Other liabilities assumed ( 1,427 ) Total transaction price $ 159,076

License Agreements

License Agreements	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License Agreements	10. License agreements Harvard license agreement Under the Harvard License Agreement, Harvard is entitled to receive success payments, in cash or shares of Company stock, determined based upon the achievement of specified multiples of the initial weighted average value of the Company’s Series A Preferred Stock at specified valuation dates. The success payments range from $ 5.0 million to a maximum of $ 105.0 million and have valuation multiples that range from 5 times to 40 times the initial weighted average value of the Series A Preferred Stock. Subsequent to the Company’s IPO, the amount of success payments is based on the market value of the Company’s common stock. The Company is required to make success payments to Harvard during a period of time, or the Harvard Success Payment Period, which has been determined to be the later of (1) the ninth anniversary of the Harvard License Agreement or (2) the earlier of (a) the twelfth anniversary of the Harvard License Agreement and (b) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Harvard Success Payment Period and beginning one year after the Company’s IPO, the Company will perform a calculation of any amounts owed to Harvard on each rolling 90-day period. In May 2021, the first success payment measurement occurred and amounts due to Harvard were calculated to be $ 15.0 million. The Company elected to make the payment in shares of the Company’s common stock and issued 174,825 shares of the Company’s common stock to settle this liability on June 10, 2021. The Company may owe Harvard success payments of up to an additional $ 90.0 million. As of September 30, 2022 , no success payments were due to Harvard. The following table summarizes the Company’s success payment liability for Harvard (in thousands): September 30, December 31, Harvard success payment liability $ 10,500 $ 21,000 The following table summarizes the expense resulting from the change in the fair value of the success payment liability for Harvard (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Change in fair value of Harvard success payment liability $ 2,400 $ ( 17,900 ) $ ( 10,500 ) $ 4,200 The annual maintenance fee under the Harvard License Agreement is recorded as research and development expense. Annual patent costs will be expensed as incurred. As of September 30, 2022 , the Company determined that product development and regulatory approval milestones under the Harvard License Agreement were not probable and, as such, no amounts were recognized for the three and nine months ended September 30, 2022 or 2021. During the nine months ended September 30, 2022, the Company incurred $ 2.7 million of expense related to non-royalty sublicense fees owed to Harvard. There was no expense recognized related to non-royalty sublicense fees owed to Harvard during the three months ended September 30, 2022. Additionally, during the nine months ended September 30, 2022, the Company paid $ 35.3 million of non-royalty sublicense fees to Harvard related to non-royalty sublicense fee expense incurred during the second half of 2021 and the first half of 2022. The Company recognized expense related to non-royalty sublicense fees owed to Harvard during the three and nine months ended September 30, 2021 of $ 1.6 million and $ 2.7 million, respectively. Broad license agreement Under the Broad License Agreement, Broad Institute is entitled to receive success payments, in cash or shares of Company common stock, determined based upon the achievement of specified multiples of the initial weighted average value of the Series A Preferred Stock at specified valuation dates. The success payments range from $ 5.0 million to a maximum of $ 105.0 million and have valuation multiples that range from 5 times to 40 times the initial weighted average value of the Series A Preferred Stock. Subsequent to the Company's IPO, the amount of success payments is based on the market value of the Company’s common stock. The Company is required to make success payments to Broad Institute during a period of time, or the Broad Success Payment Period, which has been determined to be the earliest of (1) the twelfth anniversary of the Broad License Agreement or (2) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Broad Success Payment Period and beginning one year after the Company’s IPO, the Company will perform a calculation of any amounts owed to Broad Institute on each rolling 90-day period. In May 2021, the first success payment measurement occurred and amounts due to Broad Institute were calculated to be $ 15.0 million. The Company elected to make the payment in shares of the Company’s common stock and issued 174,825 shares of the Company’s common stock to settle this liability on June 10, 2021. The Company may owe Broad Institute success payments of up to an additional $ 90.0 million. As of September 30, 2022 , no success payments were due to Broad Institute. The following table summarizes the Company’s success payment liability for Broad Institute (in thousands): September 30, December 31, Broad Institute success payment liability $ 10,800 $ 21,200 The following table summarizes the expense resulting from the change in the fair value of the success payment liability for Broad Institute (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Change in fair value of Broad Institute success payment liability $ 2,500 $ ( 17,900 ) $ ( 10,400 ) $ 4,200 The annual maintenance fee under the Broad License Agreement is recorded as research and development expense. Annual patent costs will be expensed as incurred. As of September 30, 2022, the Company determined that product development and regulatory approval milestones and royalties under the Broad License Agreement were not probable and, as such, no amounts were recognized for the three and nine months ended September 30, 2022 . There was no expense recorded for these milestones for the three and nine months ended September 30, 2022 or 2021. The Company paid $ 6.1 million of non-royalty sublicense fees to Broad Institute during the nine months ended September 30, 2022 related to non-royalty sublicense fee expense incurred during the second half of 2021. As of September 30, 2022 , the Company has no amounts accrued for non-royalty sublicense fees due to Broad Institute. The Company recorded no expense related to non-royalty sublicense fees owed to the Broad Institute during the three and nine months ended September 30, 2022 or 2021. Editas license agreement In May 2018, the Company entered into a license agreement, or the Editas License Agreement, with Editas Medicine, Inc., or Editas. Pursuant to the Editas License Agreement, Editas granted to the Company licenses and options to acquire licenses to certain intellectual property rights owned or controlled by Editas, for specified uses. The annual maintenance fees under the Editas License Agreement are recorded as research and development expense. Annual patent costs are expensed as incurred. In addition, the Company is required to make certain development, regulatory and commercial milestone payments to Editas upon the achievement of specified milestones. Management concluded that the licenses acquired from each transaction above did not meet the accounting definition of a business as inputs, but no processes or outputs were acquired with the licenses, and the licensed technology had not achieved technological feasibility. As the inputs that were acquired along with the licenses do not constitute a “business,” the transactions have been accounted as asset acquisitions.

Collaboration and License Agree

Collaboration and License Agreements	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration and License Agreements	11. Collaboration and license agreements Orbital In September 2022, the Company entered into the Orbital Agreement and the Orbital Issuance Agreement with Orbital. Under the terms of the Orbital Agreement, the Company will collaborate with Orbital to advance nonviral delivery and RNA technology by providing Orbital with certain proprietary materials, a non-exclusive research license to certain RNA technology and nonviral delivery technology controlled by the Company, and by performing research and development support services as outlined in a research plan. The Company also granted Orbital an exploitation license to certain RNA technology and nonviral delivery technology controlled by the Company. The exploitation license is exclusive in the fields of vaccines and certain protein therapeutics and nonexclusive in all other fields other than gene editing and conditioning. The collaboration is managed on an overall basis by a Joint Steering Committee, or JSC, comprised of an equal number of representatives from the Company and Orbital. In exchange for the licenses and services provided by the Company under the Orbital Agreement, the Company received a non-exclusive research license to certain RNA technology and nonviral delivery technology controlled by Orbital, and research and development support services as outlined in a research plan. Orbital also granted Beam an exploitation license to certain RNA technology and nonviral delivery technology controlled by Orbital. The exploitation license is exclusive in the fields of gene editing and conditioning and nonexclusive in all other fields other than vaccines and certain protein therapeutics. The Company also received 75 million shares of Orbital’s common stock at closing, which represents a 31.5 % fully diluted equity interest in Orbital. The Company accounts for its investment in Orbital under the equity method of accounting. Refer to Note 8 for further details. The research plan has a term of three years and can be extended for unspecified periods upon mutual agreement between the Company and Orbital. The exploitation licenses are exclusive for an initial research term of three years , which may be extended for up to two successive one-year periods by mutual agreement between the Company and Orbital. Either party may terminate the licenses granted to it under the Orbital Agreement for convenience on a product-by-product basis at any time by providing 90 days’ prior written notice. The Company accounts for the Orbital Agreement under ASC 606, Revenue from Contracts with Customers , or ASC 606, as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract. The overall transaction price as of the inception of the contract was determined to be $ 25.5 million, which represents the fair value of the Company’s equity interest in Orbital’s common stock at inception. See Note 8 for the determination of the fair value of the Company’s investment. There is no variable consideration included in the transaction price at inception. The Company concluded that the research and exploitation licenses are not distinct from the other promises in the Orbital Agreement, and as such the Company has determined that the licenses combined with the research and development services, know-how transfers, committee participation and materials transfer represent a performance obligation. The Company plans to recognize revenue for the performance obligation over time as it is satisfied during the term of the agreement. As no activities under the Orbital Agreement had commenced as of September 30, 2022 , the entire $ 25.5 million is recorded as deferred revenue and no revenue was recognized during the three and nine months ended September 30, 2022 . Based on the current estimated timelines, the deferred revenue is expected to be recognized as revenue over approximately three years from September 30, 2022. As of September 30, 2022, there was $ 8.5 million and $ 17.0 million of current and long-term deferred revenue, respectively, related to the Orbital Agreement. Pfizer In December 2021, the Company entered into a research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on the use of certain of the Company’s base editing technology to develop in vivo therapies for rare genetic diseases of the liver, muscle, and central nervous system. Under the terms of the Pfizer Agreement, the Company will conduct all research activities through development candidate selection for three base editing programs that target specific genes corresponding to specific diseases that are the subject of such programs. Pfizer will have exclusive rights to license each of the three programs at no additional cost, each an Opt-In Right, and will assume responsibility for subsequent development and commercialization. At the end of the Phase 1/2 clinical trials, the Company may elect to enter into a global co-development and co-commercialization agreement with Pfizer with respect to one program licensed under the collaboration for an option exercise fee equal to a percentage of the applicable development costs incurred by Pfizer, or the Participation Election. In the event the Company elects to exercise its Participation Election, upon the payment of its option exercise fee, Pfizer and the Company would share net profits as well as development and commercialization costs in a 65 %/ 35 % (Pfizer/Company) split for such program. The research collaboration is managed on an overall basis by a Joint Research Committee, or JRC, formed by an equal number of representatives from the Company and Pfizer. At the inception of the Pfizer Agreement, the Company was entitled to receive a nonrefundable upfront payment of $ 300.0 million in consideration for the rights granted to Pfizer under the collaboration. Should Pfizer exercise its Opt-In Right for any of the three programs, the Company would be eligible to receive development, regulatory, and commercial milestones of up to $ 350.0 million per program, for potential total consideration of up to $ 1.35 billion, plus royalty payments on global net sales for each licensed program, if any. If Pfizer does not exercise its Opt-In Right for a program, the Company’s rights in such program revert to the Company and the Company will be required to pay Pfizer earn-out payments equal to a low single digit percentage of net sales earned on such program for a ten-year period, if any. As the $ 300.0 million upfront fee was not received by the Company as of December 31, 2021, the Company recorded a collaboration receivable for $ 300.0 million with a corresponding deferred revenue liability. The Company received the $ 300.0 million in January 2022. During the collaboration term, Pfizer has a one-time option to substitute a disease that is the subject of a specific program with one pre-defined substitute disease. The collaboration has an initial term of four years and may be extended for an additional year on a program-by-program basis . Pfizer may terminate the Pfizer Agreement for convenience on any or all of the programs by providing 90 days’ prior written notice. The Company accounts for the Pfizer Agreement under ASC 606 as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract. The overall transaction price as of the inception of the contract was determined to be $ 300.0 million, which is comprised entirely of the nonrefundable upfront payment. There is no variable consideration included in the transaction price at inception as the future milestone payments are fully constrained and the Company is not required to estimate variable consideration for the royalty payments at contract inception. The Company will re-evaluate the transaction price in each reporting period. The Company has concluded that the licenses to its base editing technology, including the exclusive development and commercialization rights, are not capable of being distinct from the other performance obligations, and as such the Company has determined that the licenses combined with the other research and development services represent performance obligations and no up-front revenue was recognized for the licenses. The selling price of each performance obligation was determined based on the Company’s estimated standalone selling price, or the ESSP. The Company developed the ESSP for all of the performance obligations included in the Pfizer Agreement with the objective of determining the price at which it would sell such an item if it were to be sold regularly on a standalone basis. The Company allocated the stand-alone selling price to the performance obligations based on the relative standalone selling price method. The Company recognizes revenue for each performance obligation as it is satisfied during the term of the agreement using an input method. The Company allocated the transaction price of $ 300.0 million to each of the three performance obligations, which includes each of the three base editing programs combined with the research and development services, licenses, and exclusive development and commercialization rights. Revenue is recognized using an input method based on the actual costs incurred as a percentage of total budgeted costs towards satisfying the performance obligation as this method provides the most faithful depiction of the entity’s performance in transferring control of the goods and services promised to Pfizer and represents the Company’s best estimate of the period of the obligation. For the three and nine months ended September 30, 2022, the Company recognized $ 12.8 million and $ 33.4 million of revenue related to the Pfizer Agreement, respectively. As of September 30, 2022, there was $ 123.6 million and $ 143.0 million of current and long-term deferred revenue, respectively, related to the Pfizer Agreement. There was no revenue recognized related to the Pfizer Agreement during the three or nine months ended September 30, 2021. Apellis Pharmaceuticals In June 2021, the Company entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of the Company’s base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the Apellis Agreement, the Company will conduct preclinical research on up to six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis has an exclusive option to license any or all of the six programs, or in each case, an Opt-In Right, and will assume responsibility for subsequent development. The Company may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program instead of a license. The collaboration is managed on an overall basis by an alliance steering committee formed by an equal number of representatives from the Company and Apellis. As part of the collaboration, the Company was eligible to receive a total of $ 75.0 million in upfront and near-term milestone payments from Apellis, which was comprised of $ 50.0 million received upon signing and an additional $ 25.0 million payment to be paid on the one-year anniversary of the effective date of the Apellis Agreement, or the First Anniversary Payment. The Company received the $ 25.0 million First Anniversary Payment from Apellis during the nine months ended September 30, 2022. Following any exercise of an Opt-In Right for any of the six programs, the Company will be eligible to receive development, regulatory, and sales milestones from Apellis, as well as royalty payments on sales. The collaboration has an initial term of five years and may be extended up to two years on a per year and program-by-program basis. During the collaboration term, Apellis may, subject to certain limitations, substitute a specific complement gene and/or organ for any of the initial base editing programs. Apellis may terminate the Apellis Agreement for convenience on any or all of the programs by providing prior written notice. The Company accounts for the Apellis Agreement under ASC 606 as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract. The overall transaction price as of the inception of the contract was determined to be $ 75.0 million, which is composed of the upfront payment of $ 50.0 million and the First Anniversary Payment of $ 25.0 million. The Company will re-evaluate the transaction price in each reporting period. The Company concluded that each of the six base editing programs combined with the research and development service, licenses, substitution rights and governance participation were material promises that were both capable of being distinct and were distinct within the context of the Apellis Agreement and represented separate performance obligations. Therefore, the Company did no t recognize any upfront revenue related to the license. The Company further concluded that the Opt-In Rights and option to extend the collaboration term did not grant Apellis a material right. The Company determined that the term of the contract is five years , as this is the period during which both parties have enforceable rights. The selling price of each performance obligation was determined based on the Company’s estimated standalone selling price, or the ESSP. The Company developed the ESSP for all of the performance obligations included in the Apellis Agreement with the objective of determining the price at which it would sell such an item if it were to be sold regularly on a standalone basis. The Company allocated the stand-alone selling price to the performance obligations based on the relative standalone selling price method. The Company recognizes revenue for each performance obligation as it is satisfied over the five-year term using an input method. The Company allocated the transaction price of $ 75.0 million to each of the six performance obligations, which includes each of the six base editing programs combined with the research and development service, licenses, substitution rights and governance participation, and is being recognized using an input method based on the actual costs incurred as a percentage of total budgeted costs towards satisfying the performance obligation as this method provides the most faithful depiction of the entity’s performance in transferring control of the goods and services promised to Apellis and represents the Company’s best estimate of the period of the obligation. For the three and nine months ended September 30, 2022, the Company recognized $ 3.0 million and $ 7.5 million of revenue related to the Apellis Agreement, respectively. As of September 30, 2022, there is $ 27.8 million and $ 37.9 million of current and long-term deferred revenue, respectively, related to the Apellis Agreement. For the three and nine months ended September 30, 2021, the Company recognized $ 0.8 million of revenue related to the Apellis Agreement. Prime Medicine In September 2019, the Company entered into a collaboration and license agreement, or the Prime Agreement, with Prime Medicine, Inc., or Prime, to research and develop a novel gene editing technology developed by one of the Company’s founders. Under the terms of the agreement, the Company granted Prime Medicine a non-exclusive license to certain of its CRISPR technology (including Cas12b), delivery technology and certain other technology controlled by the Company to develop and commercialize gene editing products for the treatment of human diseases. Prime Medicine granted the Company an exclusive license to develop and commercialize prime gene editing technology for the creation or modification of any single base transition mutations, as well as any edits made for the treatment of sickle cell disease. Additionally, each party granted to the other party certain exclusive and non-exclusive licenses to certain technology developed after the effective date of the agreement and controlled by the granting party or jointly owned by the parties. Each party has an obligation to assign rights in certain technology developed under the collaboration to the other party. The Company provided immaterial interim management and startup services to Prime Medicine through March 2021 but did not provide any such services during 2022. As of September 30, 2022, the Company determined that future milestones and royalties under the Prime Agreement were not probable of recognition. Verve In April 2019, the Company entered into a collaboration and license agreement with Verve, or the Verve Agreement, to investigate gene editing strategies to modify genes associated with an increased risk of coronary diseases and in July 2022, the Company and Verve amended the Verve Agreement. Under the terms of the Verve Agreement, as amended, the Company granted Verve an exclusive license to certain base editor technology and improvements and Verve granted Beam a non-exclusive license under certain know-how and patents controlled by Verve, an interest in joint collaboration technology and a non-exclusive license under certain delivery technology. As of September 30, 2022 , the Company determined that milestones and royalties under the Verve Agreement were not probable of recognition.

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2022
Stockholders' Equity Attributable to Parent [Abstract]
Common Stock	12. Common stock In January 2021, the Company issued and sold 2,795,700 shares of its common stock in a private placement at an offering price of $ 93.00 per share for aggregate gross proceeds of $ 260.0 million. The Company received $ 252.0 million in net proceeds after deducting fees to the placement agents and offering expenses payable by the Company. In April 2021, the Company entered into the Sales Agreement, with Jefferies, pursuant to which the Company was entitled to offer and sell, from time to time at prevailing market prices, shares of the Company’s common stock having aggregate gross proceeds of up to $ 300.0 million. The Company agreed to pay Jefferies a commission of up to 3.0 % of the aggregate gross sale proceeds of any shares sold by Jefferies under the Sales Agreement. Between April and July 2021, the Company has sold 2,908,009 shares of its common stock under the Sales Agreement at an average price of $ 103.16 per share for aggregate gross proceeds of $ 300.0 million, before deducting commissions and offering expenses payable by the Company. In July 2021, the Company and Jefferies entered into an amendment to the Sales Agreement to provide for an increase in the aggregate offering amount under the Sales Agreement, such that as of July 7, 2021, the Company may offer and sell shares of common stock having an aggregate offering price of an additional $ 500.0 million. As of September 30, 2022, the Company has sold 3,248,633 additional shares of its common stock under the amended Sales Agreement at an average price of $ 89.06 per share for aggregate gross proceeds of $ 289.3 million, before deducting commissions and offering expenses payable by the Company. The holders of the Company’s common stock are entitled to one vote for each share of common stock. Subject to the payment in full of all preferential dividends to which the holders of the Company’s preferred stock are entitled, the holders of the Company’s common stock shall be entitled to receive ratably dividends out of funds legally available. In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company and all preferential amounts to which the holders of Company’s preferred stock are entitled with respect to the distribution of assets in liquidation, the holders of common stock shall be entitled to share ratably in the remaining assets of the Company available for distribution.

Stock Option and Grant Plan

Stock Option and Grant Plan	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock Option and Grant Plan	13. Stock option and grant plan 2017 stock option and grant plan In June 2017, the Company’s board of directors adopted the Beam Therapeutics Inc. 2017 Stock Option and Grant Plan, or the 2017 Plan, which provided for the grant of qualified incentive stock options and nonqualified stock options, restricted stock or other awards to the Company’s employees, officers, directors, advisors, and outside consultants for the issuance or purchase of shares of the Company’s common stock. In May 2019, the 2017 Plan was amended to provide up to 8,078,681 shares of common stock for the issuance of stock options and restricted stock. 2019 equity incentive plan In October 2019, the Company’s board of directors adopted the Beam Therapeutics Inc. 2019 Equity Incentive Plan, or the 2019 Plan, and, following the IPO, all equity-based awards have been granted under the 2019 Plan. The 2019 Plan provides for the grant of qualified and nonqualified stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, and other share-based awards to the Company’s employees, officers, directors, advisors, and outside consultants. The maximum number of shares of the Company’s common stock that may be issued under the 2019 Plan was initially 3,700,000 shares, or the Share Pool, plus the number of shares of the Company’s common stock underlying awards under the 2017 Plan, not to exceed 5,639,818 shares, that become available again for grant under the 2017 Plan in accordance with its terms. The Share Pool will automatically increase on January 1st of each year from 2021 to 2029 by the lesser of (i) 4.0 % of the number of shares of the Company’s common stock outstanding as of the close of business on the immediately preceding December 31st and (ii) the number of shares determined by the Company’s board of directors on or prior to such date for such year. As of September 30, 2022, the Company had 10,947,167 shares reserved including 1,703,263 shares available for future issuance pursuant to the 2019 Plan. Stock-based compensation expense recorded as research and development and general and administrative expenses in the condensed consolidated statements of operations and other comprehensive loss is as follows (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Research and development $ 13,859 $ 7,554 38,581 17,049 General and administrative 8,350 5,414 23,241 11,019 Total stock-based compensation expense $ 22,209 $ 12,968 $ 61,822 $ 28,068 Stock options The following table provides a summary of option activity under the Company’s equity award plans: Number Weighted Outstanding at December 31, 2021 6,034,192 $ 32.40 Granted 2,051,846 62.32 Exercised ( 369,444 ) 5.33 Forfeitures ( 109,531 ) 55.89 Outstanding at September 30, 2022 7,607,063 41.45 Exercisable as of September 30, 2022 3,421,139 24.52 The weighted-average grant date fair value per share of options granted in the nine months ended September 30, 2022 was $ 41.84 . As of September 30, 2022, there was $ 148.5 million of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately 2.4 years. Restricted stock The Company issues shares of restricted common stock, including both restricted stock units and restricted stock awards. Restricted common stock issued generally vests over a period of two to four years . The following table summarizes the Company’s restricted stock activity: Shares Weighted- Unvested as of December 31, 2021 1,126,206 $ 74.32 Issued 937,725 53.52 Vested ( 379,287 ) 51.00 Forfeited ( 36,865 ) 75.65 Unvested as of September 30, 2022 1,647,779 $ 67.82 At September 30, 2022, there was approximately $ 98.3 million of unrecognized stock-based compensation expense related to restricted stock that is expected to vest. These costs are expected to be recognized over a weighted-average remaining vesting period of approximately 3.2 years. 2019 employee stock purchase plan In February 2020, the Company’s board of directors adopted the Beam Therapeutics Inc. 2019 Employee Stock Purchase Plan, or ESPP, which was approved by the Company’s stockholders. Pursuant to the ESPP, certain employees of the Company, excluding consultants and non-employee directors, are eligible to purchase common stock of the Company at a reduced rate during offering periods. The ESPP permits participants to purchase common stock using funds contributed through payroll deductions, subject to a calendar year limit of $ 25,000 and at a purchase price of 85 % of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the applicable purchase date, which will be the final trading day of the applicable purchase period. The ESPP has two annual purchase periods extending from October to March and April to September. The Company issued 41,083 and 70,073 shares under the ESPP during the three and nine months ended September 30, 2022, respectively. There were no shares issued under the ESPP during the nine months ended September 30, 2021. As of September 30, 2022 , the Company had 1,665,199 shares available for issuance under the ESPP. Stock-based compensation recognized under the ESPP for the three and nine months ended September 30, 2022 was $ 0.2 million and $ 1.1 million, respectively. There was no stock-based compensation expense recorded under the ESPP for the three and nine months ended September 30, 2021 .

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Loss per Share	14. Net loss per share For periods in which the Company reports a net loss, potentially dilutive securities have been excluded from the computation of diluted net loss per share as their effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share because including them would have had an anti-dilutive effect: As of September 30, 2022 2021 Unvested restricted stock 1,647,779 1,286,834 Outstanding options to purchase common stock 7,607,063 6,139,250 Total 9,254,842 7,426,084 The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands, except share and per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Numerator: Net loss $ ( 109,575 ) $ ( 28,118 ) $ ( 250,739 ) $ ( 305,931 ) Denominator: Weighted average common shares outstanding, basic and diluted 70,343,196 66,377,611 69,758,434 62,960,219 Net loss per common share, basic and diluted $ ( 1.56 ) $ ( 0.42 ) $ ( 3.59 ) $ ( 4.86 )

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	15. Income taxes During the three and nine months ended September 30, 2022 , the Company recorded an income tax provision of $ 2.4 million. During the three and nine months ended September 30, 2021 , the Company did no t record a tax provision. The income tax provision for the period ended September 30, 2022 is primarily attributable to the recognition of revenue for tax purposes under the collaboration agreements with Apellis and Pfizer, which was deferred in 2021 for tax purposes. In addition, the Tax Cuts and Jobs Act of 2017 eliminates the option to deduct research and development expenditures currently and requires taxpayers to capitalize and amortize them over five or fifteen years pursuant to Section 174 of the Internal Revenue Code of 1986, as amended. Utilization of the net operating loss, or NOL, and research and development credit carryforwards may be subject to a substantial annual limitation under Section 382 and 383 of the Internal Revenue Code due to ownership change limitations that have occurred previously, or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company has completed a Section 382 study as of December 31, 2021. As of December 31, 2021 the Company had $ 374.4 million of federal net operating losses available, subject to an 80 % limitation. The Company evaluates the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective evidence evaluated was the cumulative loss incurred over the three-year period ended June 30, 2022 and that the Company has historically generated pretax losses. Such objective evidence limits the ability to consider other subjective evidence, such as projections for future growth. On the basis of this evaluation, as of June 30, 2022, the Company continued to maintain a full valuation allowance against its deferred tax assets, except to the extent NOLs have been used to reduce taxable income.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	16. Related party transactions Orbital As described in Note 8, the Company has significant influence over, but does not control, Orbital through its noncontrolling representation on Orbital's board of directors and the Company’s equity interest in Orbital. The Company and Orbital are also parties to a collaboration and license agreement and have multiple common board members. The Company has a 31.5 % equity interest in Orbital as of September 30, 2022. Verve The Company and Verve are parties to a collaboration and license agreement and had a common board member through the first half of 2022. Prior to Verve’s initial public offering in June 2021, the Company owned both common and preferred shares of Verve and valued such investment based on the cost of the equity securities adjusted for any observable market transactions. Following Verve’s initial public offering, and the conversion of the preferred stock to common stock and a stock split, the equity securities have a readily determinable fair value and the Company owned 546,970 shares of Verve's common stock, the value of which is included in marketable securities in the condensed consolidated balance sheet. The Company recorded the investment at fair value as of September 30, 2022, which resulted in the recognition of other income of $ 10.4 millio n and other expense of $ 1.4 million for the three and nine months ended September 30, 2022, respectively. The Company recorded other expense of $ 4.9 million and other income of $ 22.0 million for the three and nine months ended September 30, 2021, respectively related to the changes in fair value of Verve's common stock. The fair value of this investment as of September 30, 2022 is $ 18.8 million. The Company purchased certain materials from Verve amounting to $ 0.4 million, which are recorded as research and development expenses within the accompanying condensed consolidated statements of operations and other comprehensive loss, for the three and nine months ended September 30, 2022. The Company purchased $ 0.2 million of materials from Verve during the nine months ended September 30, 2021. In October 2021, the Company entered into an agreement pursuant to which Verve subleased 12,000 square feet of the Company’s existing office and laboratory space for a term of one year which began in December 2021 . Verve is expected to pay approximately $ 1.4 million in rental payments over the term of the sublease, as well as its proportionate costs for the landlord’s operating expense, insurance, property taxes, and utilities. The Company recorded $ 0.3 million and $ 1.0 million of sublease income related to this sublease within the accompanying consolidated statements of operations and other comprehensive loss for the three and nine months ended September 30, 2022, respectively. Prime Medicine The Company and Prime Medicine are parties to the Prime Agreement and have a common founder and had a common board member through the first half of 2022. Additionally, in September 2019, in connection with the Prime Agreement, the Company executed a letter agreement, as amended, to provide certain interim management and startup services to Prime Medicine through March 2021. Prime Medicine was obligated to reimburse the Company’s out-of-pocket costs incurred in connection with performing these services and, beginning in October 2020 and ending in March 2021, paid the Company a $ 30.0 thousand monthly service fee. There were no interim management and startup services provided to Prime Medicine during the three and nine months ended September 30, 2022. Founders The Company made payments of $ 0.1 million and $ 0.3 million to its three founder shareholders for scientific consulting and other expenses for each of the three and nine months ended September 30, 2022 and 2021.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of presentation The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board.
Principles of Consolidation	Principles of consolidation The accompanying condensed consolidated financial statements include the results of operations of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates	Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, incremental borrowing rate used in the calculation of lease liabilities, research and development expenses, stock-based compensation, contingent consideration liabilities, success payments and certain judgements regarding revenue recognition. Actual results could differ from these estimates.
Cash, Cash Equivalents, and Restricted Cash	Cash, cash equivalents, and restricted cash Cash and cash equivalents consist of standard checking accounts, money market accounts, and all highly liquid investments with a remaining maturity of three months or less at the date of purchase. Restricted cash represents collateral provided for letters of credit issued as security deposits in connection with the Company’s leases of its corporate and manufacturing facilities. The following table reconciles cash, cash equivalents, and restricted cash reported within the Company’s condensed consolidated balance sheets to the total of the amounts shown in the condensed consolidated statements of cash flows (in thousands): September 30, September 30, Cash and cash equivalents $ 156,511 $ 612,023 Restricted cash 12,750 14,840 Total cash, cash equivalents, and restricted cash $ 169,261 $ 626,863
Equity Method of Accounting	Equity method of accounting In circumstances where the Company has the ability to exercise significant influence, but not control, over the operating and financial policies of an entity in which the Company has an investment in common stock or in-substance common stock, the Company utilizes the equity method of accounting for recording related investment activity. In assessing whether the Company exercises significant influence, the Company considers the nature and magnitude of the investment, participating rights the Company holds, and relevant factors such as the presence of a collaborative or other business relationship. Under the equity method of accounting, the Company’s investments are initially recorded at cost on the consolidated balance sheets. Upon recording an equity method investment, the Company evaluates whether there are basis differences between the carrying value and fair value of the Company’s proportionate share of the investee’s underlying net assets. Typically, the Company amortizes basis differences identified on a straight-line basis over the underlying asset’s or liability's estimated useful lives when calculating the attributable earnings or losses, excluding the basis differences attributable to in-process research and development, or IPR&D, that has no alternative future use. To the extent a basis difference relates to IPR&D and the investee is not a business as defined in ASC 805, the Company immediately expenses such basis difference related to IPR&D. If the Company is unable to attribute all of the basis difference to specific assets or liabilities of the investee, the residual excess of the cost of the investment over the proportional fair value of the investee’s assets and liabilities is considered to be Equity Method Goodwill and is recognized within the equity investment balance, which is tracked separately within the Company’s memo accounts. The Company subsequently records in the consolidated statements of operations and comprehensive loss its share of income or loss of the other entity within the loss from equity method investment line item. If the share of losses exceeds the carrying value of the Company’s investment, the Company will suspend recognizing additional losses and will continue to do so unless it commits to providing additional funding. The Company evaluates its equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amounts of such investments may be impaired and considers qualitative and quantitative factors including the investee’s financial metrics, product and commercial outlook and cash usage. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period and the investment is written down to fair value. At September 30, 2022 , the Company accounted for its investment in Orbital Therapeutics, Inc., or Orbital, under the equity method of accounting. Refer to Note 8 for further details.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Reconciliation of Cash, Cash Equivalents, and Restricted Cash	The following table reconciles cash, cash equivalents, and restricted cash reported within the Company’s condensed consolidated balance sheets to the total of the amounts shown in the condensed consolidated statements of cash flows (in thousands): September 30, September 30, Cash and cash equivalents $ 156,511 $ 612,023 Restricted cash 12,750 14,840 Total cash, cash equivalents, and restricted cash $ 169,261 $ 626,863

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consist of the following (in thousands): September 30, December 31, Leasehold improvements $ 58,151 $ 57,760 Lab equipment 40,531 29,905 Furniture and fixtures 3,738 3,679 Computer equipment 1,925 1,646 Construction in process 33,061 7,349 Total property and equipment 137,406 100,339 Less accumulated depreciation ( 26,226 ) ( 16,081 ) Property and equipment, net $ 111,180 $ 84,258
Summary of Depreciation Expense Incurred	The following table summarizes depreciation expense incurred (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Depreciation expense $ 3,473 $ 1,675 $ 10,153 $ 4,642

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2022
Schedule of Fair Value of Financial Assets and Liabilities	The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy at September 30, 2022 (in thousands): Carrying Fair Level 1 Level 2 Level 3 Assets Cash equivalents: Money market funds $ 124,096 124,096 $ 124,096 $ — $ — Commercial paper 32,415 32,415 — 32,415 — Marketable securities: Commercial paper 621,335 621,335 — 621,335 — Corporate notes 18,921 18,921 — 18,921 — U.S. Treasury securities 224,320 224,320 — 224,320 — U.S Government securities 54,679 54,679 — 54,679 — Equity securities included in marketable securities: Corporate equity securities 18,788 18,788 18,788 — — Total assets $ 1,094,554 $ 1,094,554 $ 142,884 $ 951,670 $ — Liabilities Success payment liability – Harvard $ 10,500 $ 10,500 $ — $ — $ 10,500 Success payment liability – Broad Institute 10,800 10,800 — — 10,800 Contingent consideration liability – Technology 25,835 25,835 — — 25,835 Contingent consideration liability – Product 6,075 6,075 — — 6,075 Total liabilities $ 53,210 $ 53,210 $ — $ — $ 53,210 The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy at December 31, 2021 (in thousands): Carrying Fair Level 1 Level 2 Level 3 Assets Cash equivalents: Money market funds $ 540,094 $ 540,094 $ 540,094 $ — $ — Commercial paper 13,997 13,997 — 13,997 — Corporate notes 5,903 5,903 — 5,903 — Marketable securities: Commercial paper 368,743 368,743 — 368,743 — Corporate notes 16,743 16,743 — 16,743 — Equity securities included in marketable securities: Corporate equity securities 20,167 20,167 20,167 — — Total assets $ 965,647 $ 965,647 $ 560,261 $ 405,386 $ — Liabilities Success payment liability – Harvard $ 21,000 $ 21,000 $ — $ — $ 21,000 Success payment liability – Broad Institute 21,200 21,200 — — 21,200 Contingent consideration liability – Technology 24,359 $ 24,359 — — 24,359 Contingent consideration liability – Product 7,008 7,008 — — 7,008 Total liabilities $ 73,567 $ 73,567 $ — $ — $ 73,567
Summary Of Other Income (Expense) Incurred Due To Changes In Fair Value Of Corporate Equity Securities Held	The following table summarizes other income (expense) incurred due to changes in the fair value of corporate equity securities held (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Other income (expense) $ 10,431 $ ( 4,892 ) $ ( 1,378 ) $ 21,960
Success Payment Liabilities
Schedule of Variables Included in Calculation of Estimated Fair Value	The following variables were incorporated in the calculation of the estimated fair value of the Harvard and Broad Institute success payment liabilities: Harvard Broad Institute September 30, December 31, September 30, December 31, Fair value of common stock (per share) $ 47.64 $ 79.69 $ 47.64 $ 79.69 Expected volatility 82 % 76 % 82 % 76 % Expected term (years) 0.09 - 6.75 0.10 - 7.49 0.09 - 7.61 0.10 - 8.36
Schedule of change in Fair Value of Liabilities based on Level 3 inputs	The following table reconciles the change in the fair value of success payment liabilities based on Level 3 inputs (in thousands): Nine Months Ended September 30, 2022 Harvard Broad Institute Total Balance at December 31, 2021 $ 21,000 $ 21,200 $ 42,200 Change in fair value ( 10,500 ) ( 10,400 ) ( 20,900 ) Balance at September 30, 2022 $ 10,500 $ 10,800 $ 21,300
Contingent Consideration Liabilities
Schedule of Variables Included in Calculation of Estimated Fair Value	The following variables were incorporated in the calculation of the estimated fair value of the contingent consideration liabilities: Technology Milestones Product Milestones September 30, December 31, September 30, December 31, Discount Rate 10.50 % 7.50 % 10.50 % 7.50 % Probability of Achievement 10 - 90 % 10 - 75 % 2 - 15 % 2 - 15 % Projected Year of Achievement 2022 - 2024 2022 - 2023 2024 - 2029 2023 - 2029
Schedule of change in Fair Value of Liabilities based on Level 3 inputs	The following table reconciles the change in fair value of the contingent consideration liabilities based on level 3 inputs (in thousands): Nine Months Ended September 30, 2022 Technology Milestones Product Milestones Total Balance at December 31, 2021 $ 24,359 $ 7,008 $ 31,367 Change in fair value 1,476 ( 933 ) 543 Balance at September 30, 2022 $ 25,835 $ 6,075 $ 31,910

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Summary of Marketable Securities Held	The following table summarizes the Company’s marketable securities held at September 30, 2022 (in thousands): Amortized Cost Gross Gross Fair Value Commercial paper $ 623,804 $ 2 $ ( 2,471 ) $ 621,335 Corporate notes 19,093 — ( 172 ) 18,921 U.S. Treasury securities 226,112 — ( 1,792 ) 224,320 U.S. Government securities 54,920 — ( 241 ) 54,679 Corporate equity securities 18,788 — — 18,788 Total $ 942,717 $ 2 $ ( 4,676 ) $ 938,043 The following table summarizes the Company’s marketable securities held at December 31, 2021 (in thousands): Amortized Cost Gross Gross Fair Value Commercial paper $ 368,778 $ 32 $ ( 67 ) $ 368,743 Corporate notes 16,758 — ( 15 ) 16,743 Corporate equity securities 20,167 — — 20,167 Total $ 405,703 $ 32 $ ( 82 ) $ 405,653

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following (in thousands): September 30, December 31, Employee compensation and related benefits $ 12,004 $ 11,661 Research costs 5,363 3,133 Professional fees 3,543 3,330 Process development and manufacturing costs 4,601 3,833 Other 13,089 6,964 Total $ 38,600 $ 28,921

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Summary of Operating Lease Costs	The following table summarizes operating lease costs and sublease income (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Operating lease costs $ 5,306 $ 4,557 $ 14,161 $ 13,660 Variable lease costs 643 588 3,310 1,162 Short-term lease costs 38 383 308 761 Sublease income ( 331 ) — ( 993 ) — Total $ 5,656 $ 5,528 $ 16,786 $ 15,583
Summary of Lease Term and Discount Rate	The following table summarizes the lease term and discount rate for operating leases: September 30, December 31, Weighted-average remaining lease term (years) 11.2 11.1 Weighted-average discount rate 7.5 % 7.0 %
Summary of Lease Costs for Amounts Included in Measurement of Lease Liabilities	The following table summarizes the lease costs for amounts included in the measurement of lease liabilities (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Operating cash flows used for operating leases $ 4,603 $ 3,058 $ 14,057 $ 7,053 Operating lease liabilities arising from obtaining ROU assets 250 — 35,877 24,164
Summary of Future Minimum Lease Payments of Operating Leases	At September 30, 2022, the future minimum lease payments for the Company’s operating leases for each of the next five years and total thereafter were as follows (in thousands): Remainder of 2022 $ 4,687 2023 22,629 2024 23,614 2025 24,179 2026 21,344 Thereafter 168,733 Undiscounted lease payments 265,186 Less: imputed interest ( 90,288 ) Total operating lease liabilities $ 174,898

Guide Acquisition (Tables)

Guide Acquisition (Tables)	9 Months Ended
	Sep. 30, 2022
Business Combinations [Abstract]
Summary of Transaction Price Determined and Allocated	The transaction price was determined and allocated as follows (in thousands): Transaction price Fair value of equity instruments issued $ 120,032 Technology and product contingent consideration liabilities 36,513 Transaction costs 2,531 Total transaction price $ 159,076 Transaction price allocated In-process research and development $ 154,953 Cash acquired 3,151 Prepaid expenses and other assets 264 Property and equipment 1,835 Assembled workforce 300 Other liabilities assumed ( 1,427 ) Total transaction price $ 159,076

License Agreements (Tables)

License Agreements (Tables)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Success Payment Liability	The following table summarizes the Company’s success payment liability for Harvard (in thousands): September 30, December 31, Harvard success payment liability $ 10,500 $ 21,000 The following table summarizes the Company’s success payment liability for Broad Institute (in thousands): September 30, December 31, Broad Institute success payment liability $ 10,800 $ 21,200
Schedule of Change in Fair Value of Success Payment Liability	The following table summarizes the expense resulting from the change in the fair value of the success payment liability for Harvard (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Change in fair value of Harvard success payment liability $ 2,400 $ ( 17,900 ) $ ( 10,500 ) $ 4,200 The following table summarizes the expense resulting from the change in the fair value of the success payment liability for Broad Institute (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Change in fair value of Broad Institute success payment liability $ 2,500 $ ( 17,900 ) $ ( 10,400 ) $ 4,200

Stock Option and Grant Plan (Ta

Stock Option and Grant Plan (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Stock-based Compensation Expense	Stock-based compensation expense recorded as research and development and general and administrative expenses in the condensed consolidated statements of operations and other comprehensive loss is as follows (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Research and development $ 13,859 $ 7,554 38,581 17,049 General and administrative 8,350 5,414 23,241 11,019 Total stock-based compensation expense $ 22,209 $ 12,968 $ 61,822 $ 28,068
Summary of Option Activity Under Equity Award Plans	The following table provides a summary of option activity under the Company’s equity award plans: Number Weighted Outstanding at December 31, 2021 6,034,192 $ 32.40 Granted 2,051,846 62.32 Exercised ( 369,444 ) 5.33 Forfeitures ( 109,531 ) 55.89 Outstanding at September 30, 2022 7,607,063 41.45 Exercisable as of September 30, 2022 3,421,139 24.52
Summary of Restricted Stock Activity	The following table summarizes the Company’s restricted stock activity: Shares Weighted- Unvested as of December 31, 2021 1,126,206 $ 74.32 Issued 937,725 53.52 Vested ( 379,287 ) 51.00 Forfeited ( 36,865 ) 75.65 Unvested as of September 30, 2022 1,647,779 $ 67.82

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share	The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share because including them would have had an anti-dilutive effect: As of September 30, 2022 2021 Unvested restricted stock 1,647,779 1,286,834 Outstanding options to purchase common stock 7,607,063 6,139,250 Total 9,254,842 7,426,084
Summary of Computation of Basic and Diluted Net Loss per Share	The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands, except share and per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Numerator: Net loss $ ( 109,575 ) $ ( 28,118 ) $ ( 250,739 ) $ ( 305,931 ) Denominator: Weighted average common shares outstanding, basic and diluted 70,343,196 66,377,611 69,758,434 62,960,219 Net loss per common share, basic and diluted $ ( 1.56 ) $ ( 0.42 ) $ ( 3.59 ) $ ( 4.86 )

Nature of the Business and Ba_2

Nature of the Business and Basis of Presentation - Additional Information (Details) - USD ($)	1 Months Ended	4 Months Ended	9 Months Ended	15 Months Ended
	Apr. 30, 2021	Jul. 31, 2021	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021	Jul. 07, 2021
Nature Of Business And Basis Of Presentation [Line Items]
Accumulated deficit			$ 1,019,013,000	$ 1,019,013,000	$ 768,274,000
Cash, cash equivalents, and marketable securities			1,100,000,000	1,100,000,000
Jeffries LLC Amended Sales Agreement
Nature Of Business And Basis Of Presentation [Line Items]
Gross proceeds from issuance of common stock			$ 289,300,000	$ 289,300,000
Jeffries LLC Amended Sales Agreement | Common Stock
Nature Of Business And Basis Of Presentation [Line Items]
Stock sold during period shares, new issues				3,248,633
Price per share of stock sold			$ 89.06	$ 89.06
Jeffries LLC Amended Sales Agreement | At-The-Market
Nature Of Business And Basis Of Presentation [Line Items]
Aggregate gross proceeds of shares authorized under ATM sales agreement						$ 500,000,000
Jeffries LLC Sales Agreement
Nature Of Business And Basis Of Presentation [Line Items]
Gross proceeds from issuance of common stock		$ 300,000,000
Jeffries LLC Sales Agreement | Common Stock
Nature Of Business And Basis Of Presentation [Line Items]
Stock sold during period shares, new issues		2,908,009
Price per share of stock sold		$ 103.16
Jeffries LLC Sales Agreement | Maximum | At-The-Market
Nature Of Business And Basis Of Presentation [Line Items]
Commission rate	3%
Aggregate gross proceeds of shares authorized under ATM sales agreement	$ 300,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Cash and cash equivalents	$ 156,511	$ 559,994	$ 612,023
Restricted cash	12,750	12,746	14,840
Total cash, cash equivalents, and restricted cash	$ 169,261	$ 572,740	$ 626,863	$ 177,011

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Total property and equipment	$ 137,406	$ 100,339
Less accumulated depreciation	(26,226)	(16,081)
Property and equipment, net	111,180	84,258
Leasehold Improvements
Property Plant And Equipment [Line Items]
Total property and equipment	58,151	57,760
Lab Equipment
Property Plant And Equipment [Line Items]
Total property and equipment	40,531	29,905
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Total property and equipment	3,738	3,679
Computer Equipment
Property Plant And Equipment [Line Items]
Total property and equipment	1,925	1,646
Construction in Process
Property Plant And Equipment [Line Items]
Total property and equipment	$ 33,061	$ 7,349

Property and Equipment, Net -_2

Property and Equipment, Net - Summary of Depreciation Expense Incurred (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 3,473	$ 1,675	$ 10,153	$ 4,642

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Fair Value of Financial Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Commercial Paper
Assets
Marketable securities	$ 621,335	$ 368,743
Harvard
Liabilities
Success payment liability	10,500	21,000
Broad Institute
Liabilities
Success payment liability	10,800	21,200
Recurring | Carrying Amount
Assets
Total assets	1,094,554	965,647
Liabilities
Total liabilities	53,210	73,567
Recurring | Carrying Amount | Money Market Funds
Assets
Cash equivalents	124,096	540,094
Recurring | Carrying Amount | Commercial Paper
Assets
Cash equivalents	32,415	13,997
Marketable securities	621,335	368,743
Recurring | Carrying Amount | Corporate Notes
Assets
Cash equivalents		5,903
Marketable securities	18,921	16,743
Recurring | Carrying Amount | U.S. Treasury Securities
Assets
Marketable securities	224,320
Recurring | Carrying Amount | U.S Government securities
Assets
Marketable securities	54,679
Recurring | Carrying Amount | Corporate Equity Securities
Assets
Equity securities included in marketable securities	18,788	20,167
Recurring | Carrying Amount | Consideration of Technology Liabilities
Liabilities
Contingent consideration liability	25,835	24,359
Recurring | Carrying Amount | Contingent Consideration of Product Liabilities
Liabilities
Contingent consideration liability	6,075	7,008
Recurring | Fair Value
Assets
Total assets	1,094,554	965,647
Liabilities
Total liabilities	53,210	73,567
Recurring | Fair Value | Money Market Funds
Assets
Cash equivalents	124,096	540,094
Recurring | Fair Value | Commercial Paper
Assets
Cash equivalents	32,415	13,997
Marketable securities	621,335	368,743
Recurring | Fair Value | Corporate Notes
Assets
Cash equivalents		5,903
Marketable securities	18,921	16,743
Recurring | Fair Value | U.S. Treasury Securities
Assets
Marketable securities	224,320
Recurring | Fair Value | U.S Government securities
Assets
Marketable securities	54,679
Recurring | Fair Value | Corporate Equity Securities
Assets
Equity securities included in marketable securities	18,788	20,167
Recurring | Fair Value | Consideration of Technology Liabilities
Liabilities
Contingent consideration liability	25,835	24,359
Recurring | Fair Value | Contingent Consideration of Product Liabilities
Liabilities
Contingent consideration liability	6,075	7,008
Recurring | Fair Value | Level 1
Assets
Total assets	142,884	560,261
Recurring | Fair Value | Level 1 | Money Market Funds
Assets
Cash equivalents	124,096	540,094
Recurring | Fair Value | Level 1 | Corporate Equity Securities
Assets
Equity securities included in marketable securities	18,788	20,167
Recurring | Fair Value | Level 2
Assets
Total assets	951,670	405,386
Recurring | Fair Value | Level 2 | Commercial Paper
Assets
Cash equivalents	32,415	13,997
Marketable securities	621,335	368,743
Recurring | Fair Value | Level 2 | Corporate Notes
Assets
Cash equivalents		5,903
Marketable securities	18,921	16,743
Recurring | Fair Value | Level 2 | U.S. Treasury Securities
Assets
Marketable securities	224,320
Recurring | Fair Value | Level 2 | U.S Government securities
Assets
Marketable securities	54,679
Recurring | Fair Value | Level 3
Liabilities
Total liabilities	53,210	73,567
Recurring | Fair Value | Level 3 | Consideration of Technology Liabilities
Liabilities
Contingent consideration liability	25,835	24,359
Recurring | Fair Value | Level 3 | Contingent Consideration of Product Liabilities
Liabilities
Contingent consideration liability	6,075	7,008
Recurring | Harvard | Carrying Amount
Liabilities
Success payment liability	10,500	21,000
Recurring | Harvard | Fair Value
Liabilities
Success payment liability	10,500	21,000
Recurring | Harvard | Fair Value | Level 3
Liabilities
Success payment liability	10,500	21,000
Recurring | Broad Institute | Carrying Amount
Liabilities
Success payment liability	10,800	21,200
Recurring | Broad Institute | Fair Value
Liabilities
Success payment liability	10,800	21,200
Recurring | Broad Institute | Fair Value | Level 3
Liabilities
Success payment liability	$ 10,800	$ 21,200

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Summary Of Other Income ( Expense) Incurred Due To Changes In Fair Value Of Corporate Equity Securities Held (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Other income (expense)	$ 10,431	$ (4,892)	$ (1,378)	$ 21,960

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Schedule of Calculation of Estimated Fair Value of Success Payment Liabilities (Details) - Success Payment Liabilities	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Fair Value of Common Stock | Harvard
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Success payment liability measurement input	47.64	79.69
Fair Value of Common Stock | Broad Institute
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Success payment liability measurement input	47.64	79.69
Expected Volatility | Harvard
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Success payment liability measurement input	0.82	0.76
Expected Volatility | Broad Institute
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Success payment liability measurement input	0.82	0.76
Expected Term (years) | Minimum | Harvard
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Success payment liability, term	1 month 2 days	1 month 6 days
Expected Term (years) | Minimum | Broad Institute
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Success payment liability, term	1 month 2 days	1 month 6 days
Expected Term (years) | Maximum | Harvard
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Success payment liability, term	6 years 9 months	7 years 5 months 26 days
Expected Term (years) | Maximum | Broad Institute
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Success payment liability, term	7 years 7 months 9 days	8 years 4 months 9 days

Fair Value of Financial Instr_6

Fair Value of Financial Instruments - Schedule of Change in Fair Value of Success Payment Liabilities Based on Level 3 Inputs (Details) - Success Payment Liabilities $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	$ 42,200
Change in fair value	(20,900)
Ending Balance	21,300
Harvard
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	21,000
Change in fair value	(10,500)
Ending Balance	10,500
Broad Institute
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	21,200
Change in fair value	(10,400)
Ending Balance	$ 10,800

Fair Value of Financial Instr_7

Fair Value of Financial Instruments - Additional Information (Details) - USD ($) $ in Millions	Sep. 30, 2022	Jun. 30, 2021	Feb. 23, 2021
Verve Therapeutics, Inc.
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Equity securities	$ 18.8
Verve Therapeutics, Inc. | Common Stock
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Equity shares held	546,970	546,970
Technology Milestones | Guide Therapeutics, Inc. | Maximum | Merger Agreement | Former Stockholders and Optionholders
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Potential milestone payable in form of common stock			$ 100
Product Milestones | Guide Therapeutics, Inc. | Maximum | Merger Agreement | Former Stockholders and Optionholders
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Potential milestone payable in form of common stock			$ 220

Fair Value of Financial Instr_8

Fair Value of Financial Instruments - Schedule of Change in Fair Value of Contingent Consideration Liabilities Based on Level 3 Inputs (Details) - Contingent Consideration Liabilities $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	$ 31,367
Change in fair value	543
Ending Balance	31,910
Technology Milestones
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	24,359
Change in fair value	1,476
Ending Balance	25,835
Product Milestones
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	7,008
Change in fair value	(933)
Ending Balance	$ 6,075

Fair Value of Financial Instr_9

Fair Value of Financial Instruments - Schedule of Calculation of Estimated Fair Value of Contingent Consideration Liabilities (Details) - Contingent Consideration Liabilities	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Technology Milestones | Minimum
Derivative Liability [Abstract]
Milestone liabilities projected year of achievement	2022	2022
Technology Milestones | Maximum
Derivative Liability [Abstract]
Milestone liabilities projected year of achievement	2024	2023
Product Milestones | Minimum
Derivative Liability [Abstract]
Milestone liabilities projected year of achievement	2024	2023
Product Milestones | Maximum
Derivative Liability [Abstract]
Milestone liabilities projected year of achievement	2029	2029
Discount Rate | Technology Milestones
Derivative Liability [Abstract]
Contingent consideration liability measurement input	0.1050	0.0750
Discount Rate | Product Milestones
Derivative Liability [Abstract]
Contingent consideration liability measurement input	0.1050	0.0750
Probability of Achievement | Technology Milestones | Minimum
Derivative Liability [Abstract]
Contingent consideration liability measurement input	0.10	0.10
Probability of Achievement | Technology Milestones | Maximum
Derivative Liability [Abstract]
Contingent consideration liability measurement input	0.90	0.75
Probability of Achievement | Product Milestones | Minimum
Derivative Liability [Abstract]
Contingent consideration liability measurement input	0.02	0.02
Probability of Achievement | Product Milestones | Maximum
Derivative Liability [Abstract]
Contingent consideration liability measurement input	0.15	0.15

Marketable Securities - Summary

Marketable Securities - Summary of Marketable Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Marketable securities held, Amortized Cost	$ 942,717	$ 405,703
Marketable securities held, Gross Unrealized Gains	2	32
Marketable securities held, Gross Unrealized Losses	(4,676)	(82)
Marketable securities held, Fair Value	938,043	405,653
Commercial Paper
Debt Securities, Available-for-sale [Line Items]
Available-for-sale, Amortized Cost	623,804	368,778
Available-for-sale, Gross Unrealized Gains	2	32
Available-for-sale, Gross Unrealized Losses	(2,471)	(67)
Available-for-sale, Fair Value	621,335	368,743
Corporate Notes
Debt Securities, Available-for-sale [Line Items]
Available-for-sale, Amortized Cost	19,093	16,758
Available-for-sale, Gross Unrealized Losses	(172)	(15)
Available-for-sale, Fair Value	18,921	16,743
U.S. Treasury Securities
Debt Securities, Available-for-sale [Line Items]
Available-for-sale, Amortized Cost	226,112
Available-for-sale, Gross Unrealized Losses	(1,792)
Available-for-sale, Fair Value	224,320
U.S Government securities
Debt Securities, Available-for-sale [Line Items]
Available-for-sale, Amortized Cost	54,920
Available-for-sale, Gross Unrealized Losses	(241)
Available-for-sale, Fair Value	54,679
Corporate Equity Securities
Debt Securities, Available-for-sale [Line Items]
Equity securities, Amortized Cost	18,788	20,167
Equity securities, Fair Value	$ 18,788	$ 20,167

Marketable Securities - Additio

Marketable Securities - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Realized gains or losses recognized on sale or maturity of marketable securities	$ 0	$ 0	$ 0	$ 0
Contractual maturity dates of investments			less than one year

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Employee compensation and related benefits	$ 12,004	$ 11,661
Research costs	5,363	3,133
Professional fees	3,543	3,330
Process development and manufacturing costs	4,601	3,833
Other	13,089	6,964
Total	$ 38,600	$ 28,921

Accrued Expenses and Other Cu_4

Accrued Expenses and Other Current Liabilities - Additional Information (Details) $ in Millions	Sep. 30, 2022 USD ($)
Dispute with Research Institution
Loss Contingencies [Line Items]
Accrual liability	$ 3.4

Leases - Additional Information

Leases - Additional Information (Details) $ in Thousands

1 Months Ended

3 Months Ended

9 Months Ended

Jun. 30, 2022 USD ($)

Aug. 31, 2020 USD ($) ft² Option

Apr. 30, 2019 USD ($) Option

Oct. 31, 2018 Option

Feb. 28, 2018 USD ($) ft²

Jun. 30, 2021 USD ($)

Sep. 30, 2022 USD ($)

Mar. 31, 2023

Dec. 31, 2021 USD ($)

Aug. 31, 2021 USD ($)

Jan. 31, 2021 USD ($)

Oct. 31, 2020 USD ($)

Lessee Lease Description [Line Items]

Operating lease right-of-use assets

$ 115,534

$ 102,718

Lease liability

174,898

Office and Laboratory Space

Lessee Lease Description [Line Items]

Square feet of office and laboratory space | ft²

38,203

Operating lease, commencement month and year

2018-03

Operating lease, termination month and year

2028-09

2034-02

Operating lease, option to extend

option to extend the lease for two terms of five years each, which are not reasonably certain of exercise.

a term extension option, which is not reasonably certain of exercise.

Operating lease, existence of option to extend

true

true

Operating lease, number of renewal options | Option

2

Operating lease, option to extend term

5 years

Leasehold improvements landlord allowance

$ 23,400

$ 6,100

Increase in operating lease right-of-use assets

$ 500

Increase in operating lease liability

$ 500

Operating lease term

12 years

Lessee, operating lease, lease not yet commenced anticipated undiscounted lease payments due

$ 11,100

Office and Laboratory Space | Letter of Credit

Lessee Lease Description [Line Items]

Lessee, operating lease, security deposit

9,700

9,700

Office and Laboratory Space | First Phase of Lease in October 2020

Lessee Lease Description [Line Items]

Operating lease, commencement month and year

2020-10

Rent payments beginning month and year

2021-08

Operating lease right-of-use assets

$ 66,800

Lease liability

$ 68,800

Office and Laboratory Space | Second Phase of Lease in January 2021

Lessee Lease Description [Line Items]

Operating lease, commencement month and year

2021-01

Rent payments beginning month and year

2022-02

Operating lease right-of-use assets

$ 22,000

Lease liability

$ 23,000

Laboratory Space

Lessee Lease Description [Line Items]

Operating lease, commencement month and year

2019-04

Operating lease, termination month and year

2025-12

Operating lease, option to extend

The amended lease is subject to fixed-rate rent escalations and provides an option to extend the lease for two additional two-year periods through December 31, 2029, which are not reasonably certain of being exercised.

Operating lease, existence of option to extend

true

Operating lease, number of renewal options | Option

2

Operating lease, option to extend term

2 years

Operating lease right-of-use assets

14,100

Lease liability

$ 14,000

Manufacturing Facility

Lessee Lease Description [Line Items]

Operating lease, commencement month and year

2022-06

Operating lease, existence of option to extend

true

Operating lease, number of renewal options | Option

2

Operating lease, option to extend term

5 years

Operating lease right-of-use assets

$ 13,600

Lease liability

30,400

Tenant improvement allowance

$ 16,800

Leasehold improvements landlord allowance

$ 20,000

Manufacturing facility, number of square feet | ft²

100,000

Lessee operating lease, description

The lease will terminate 15 years from the rent commencement date. The lease is subject to fixed-rate rent escalations and provides for $20.0 million in tenant improvements and the option to extend the lease for two terms of five years each, which were not reasonably certain of exercise as of September 30, 2022. The Company determined that it is the accounting owner of all tenant improvements under the lease. Upon executing the lease in August 2020, the Company made a security deposit of $1.5 million in the form of a letter of credit, which is included in restricted cash as of September 30, 2022 and December 31, 2021. Upon commencement of this lease in June 2022, the Company recorded an operating lease ROU asset of $13.6 million and a lease liability of $30.4 million. The variance between the ROU asset and lease liability recorded relates to $16.8 million of tenant improvement allowance completed through the lease commencement date. The $16.8 million of tenant improvement allowance is presented as an operating cash inflow and investing cash outflow within the Company’s condensed consolidated statements of cash flows. The rent payments are subject to adjustment following the determination of the total project costs of the landlord and represent in substance fixed payments that are included in the total future minimum lease payments.

Manufacturing Facility | Letter of Credit

Lessee Lease Description [Line Items]

Lessee, operating lease, security deposit

$ 1,500

$ 1,500

Manufacturing Facility | Scenario Forecast

Lessee Lease Description [Line Items]

Operating lease term

15 years

Leases - Summary of Operating L

Leases - Summary of Operating Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating lease costs	$ 5,306	$ 4,557	$ 14,161	$ 13,660
Variable lease costs	643	588	3,310	1,162
Short-term lease costs	38	383	308	761
Sublease income	(331)		(993)
Total	$ 5,656	$ 5,528	$ 16,786	$ 15,583

Leases - Summary of Lease Term

Leases - Summary of Lease Term and Discount Rate (Details)	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Weighted-average remaining lease term (years)	11 years 2 months 12 days	11 years 1 month 6 days
Weighted-average discount rate	7.50%	7%

Leases - Summary of Lease Costs

Leases - Summary of Lease Costs for Amounts Included in Measurement of Lease Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating cash flows used for operating leases	$ 4,603	$ 3,058	$ 14,057	$ 7,053
Operating lease liabilities arising from obtaining ROU assets	$ 250		$ 35,877	$ 24,164

Leases - Summary of Future Mini

Leases - Summary of Future Minimum Lease Payments of Operating Leases (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Lessee, Operating Lease, Liability, to be Paid [Abstract]
Remainder of 2022	$ 4,687
2023	22,629
2024	23,614
2025	24,179
2026	21,344
Thereafter	168,733
Undiscounted lease payments	265,186
Less: imputed interest	(90,288)
Total operating lease liabilities	$ 174,898

Equity Method Investment - Addi

Equity Method Investment - Additional Information (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)
Schedule of Equity Method Investments [Line Items]
Loss from equity method investment	$ 25,500,000	$ 25,500,000
Orbital
Schedule of Equity Method Investments [Line Items]
Collaboration agreement aggregate transaction price	$ 25,500,000	$ 25,500,000
Orbital | Option Pricing Model | Volatility of Market Participants | Level 3
Schedule of Equity Method Investments [Line Items]
Alternate investment, measurement input	0.68	0.68
Orbital | Option Pricing Model | Discount for Lack of Marketability | Level 3
Schedule of Equity Method Investments [Line Items]
Alternate investment, measurement input	0.43	0.43
Orbital
Schedule of Equity Method Investments [Line Items]
Percentage of fully diluted equity interest	31.50%	31.50%
License and collaboration agreement outstanding common stock held percentage	97%	97%
Carrying value of equity method investment	$ 0	$ 0
Dividend received		$ 0

Guide Acquisition - Additional

Guide Acquisition - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended	9 Months Ended
	Feb. 23, 2021	Mar. 31, 2021	Sep. 30, 2021	Sep. 30, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Value of shares issued for upfront payment of acquisition		$ 120,032
Research and development expense			$ 154,953
Contingent consideration liabilities				$ 31,910	$ 31,367
Common Stock
Business Acquisition [Line Items]
Value of shares issued for upfront payment of acquisition		$ 10
Guide Therapeutics, Inc. | Merger Agreement
Business Acquisition [Line Items]
Business Acquisition, merger agreement date	Feb. 23, 2021
Business combination upfront consideration paid in common stock	$ 120,000
Value of shares issued for upfront payment of acquisition	120,000
Research and development expense	155,000
Contingent consideration liabilities	$ 36,500
Guide Therapeutics, Inc. | Merger Agreement | Common Stock
Business Acquisition [Line Items]
Number of shares issued for upfront payment of acquisition	1,087,153
Guide Therapeutics, Inc. | Merger Agreement | Technology Milestones | Maximum | Former Stockholders and Optionholders
Business Acquisition [Line Items]
Potential milestone payable in form of common stock	$ 100,000
Guide Therapeutics, Inc. | Merger Agreement | Product Milestones | Maximum | Former Stockholders and Optionholders
Business Acquisition [Line Items]
Potential milestone payable in form of common stock	$ 220,000

Guide Acquisition - Summary of

Guide Acquisition - Summary of Transaction Price Determined and Allocated (Details) - Guide Therapeutics, Inc. - Merger Agreement $ in Thousands	Feb. 23, 2021 USD ($)
Transaction price
Fair value of equity instruments issued	$ 120,032
Technology and product contingent consideration liabilities	36,513
Transaction costs	2,531
Total transaction price	159,076
Transaction price allocated
Cash acquired	3,151
Prepaid expenses and other assets	264
Property and equipment	1,835
Other liabilities assumed	(1,427)
Total transaction price	159,076
In-Process Research and Development
Transaction price allocated
Intangible assets	154,953
Assembled Workforce
Transaction price allocated
Intangible assets	$ 300

License Agreements - Harvard Li

License Agreements - Harvard License Agreement - Additional Information (Details) - Harvard		3 Months Ended		9 Months Ended
	Jun. 10, 2021 shares	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	May 31, 2021 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Success payment amount due		$ 0		$ 0		$ 15,000,000
Issuance of common stock for success payment liability, Shares | shares	174,825
Milestone expense		0	$ 0	0	$ 0
Non-royalty sublicense fees owed		$ 0	$ 1,600,000	2,700,000	$ 2,700,000
Non-royalty sublicense fees paid				35,300,000
Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Success payments				$ 5,000,000
Minimum | Series A Preferred Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Success Payments, valuation multiples				5
Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional success payment amount due						$ 90,000,000
Success payments				$ 105,000,000
Maximum | Series A Preferred Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Success Payments, valuation multiples				40
Success Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Agreement description				The Company is required to make success payments to Harvard during a period of time, or the Harvard Success Payment Period, which has been determined to be the later of (1) the ninth anniversary of the Harvard License Agreement or (2) the earlier of (a) the twelfth anniversary of the Harvard License Agreement and (b) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Harvard Success Payment Period and beginning one year after the Company’s IPO, the Company will perform a calculation of any amounts owed to Harvard on each rolling 90-day period.

License Agreements - Harvard _2

License Agreements - Harvard License Agreement - Success Payment Liability (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Harvard
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Success payment liability	$ 10,500	$ 21,000

License Agreements - Harvard _3

License Agreements - Harvard License Agreement - Change in Fair Value of Success Payment Liability (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Change in fair value of derivative liabilities	$ 4,900	$ (35,800)	$ (20,900)	$ 8,400
Harvard
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Change in fair value of derivative liabilities	$ 2,400	$ (17,900)	$ (10,500)	$ 4,200

License Agreements - Broad Lice

License Agreements - Broad License Agreement - Additional Information (Details) - Broad Institute		3 Months Ended		9 Months Ended
	Jun. 10, 2021 shares	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	May 31, 2021 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-royalty sublicense fees accrued		$ 0		$ 0
Success payment amount due		0		0		$ 15,000,000
Issuance of common stock for success payment liability, Shares | shares	174,825
Milestone expense		0	$ 0	0	$ 0
Non-royalty sublicense fees paid				6,100,000
Non-royalty sublicense fees owed		$ 0	$ 0	$ 0	$ 0
Success Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Agreement description				The Company is required to make success payments to Broad Institute during a period of time, or the Broad Success Payment Period, which has been determined to be the earliest of (1) the twelfth anniversary of the Broad License Agreement or (2) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Broad Success Payment Period and beginning one year after the Company’s IPO, the Company will perform a calculation of any amounts owed to Broad Institute on each rolling 90-day period.
Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Success payments				$ 5,000,000
Minimum | Series A Preferred Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Success Payments, valuation multiples				5
Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Success payments				$ 105,000,000
Additional success payment amount due						$ 90,000,000
Maximum | Series A Preferred Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Success Payments, valuation multiples				40

License Agreements - Broad Li_2

License Agreements - Broad License Agreement - Success Payment Liability (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Broad Institute
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Success payment liability	$ 10,800	$ 21,200

License Agreements - Broad Li_3

License Agreements - Broad License Agreement - Change in Fair Value of Success Payment Liability (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Change in fair value of derivative liabilities	$ 4,900	$ (35,800)	$ (20,900)	$ 8,400
Broad Institute
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Change in fair value of derivative liabilities	$ 2,500	$ (17,900)	$ (10,400)	$ 4,200

Collaboration and License Agr_2

Collaboration and License Agreements - Additional Information (Details) - USD ($) shares in Millions	1 Months Ended				3 Months Ended		9 Months Ended
	Sep. 30, 2022	Jan. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Current portion of deferred revenue	$ 159,902,000		$ 86,270,000		$ 159,902,000		$ 159,902,000
Long-term portion of deferred revenue	$ 198,288,000		$ 262,303,000		198,288,000		$ 198,288,000
Orbital
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration arrangement, initial term	3 years
Collaboration arrangement extension term description							which may be extended for up to two successive one-year periods
Collaboration agreement performance obligation revenue recognized					0		$ 0
Collaboration agreement aggregate transaction price	$ 25,500,000				25,500,000		$ 25,500,000
Collaboration agreement performance obligation revenue period for recognition							3 years
Deferred revenue	25,500,000				25,500,000		$ 25,500,000
Current portion of deferred revenue	8,500,000				8,500,000		8,500,000
Long-term portion of deferred revenue	17,000,000				17,000,000		$ 17,000,000
Apellis Pharmaceuticals, Inc
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Agreement description							In June 2021, the Company entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of the Company’s base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the Apellis Agreement, the Company will conduct preclinical research on up to six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis has an exclusive option to license any or all of the six programs, or in each case, an Opt-In Right, and will assume responsibility for subsequent development. The Company may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program instead of a license. The collaboration is managed on an overall basis by an alliance steering committee formed by an equal number of representatives from the Company and Apellis.
Collaboration arrangement, initial term				5 years
Upfront revenue recognized							$ 0
Collaboration agreement performance obligation revenue recognized					3,000,000	$ 800,000	7,500,000	$ 800,000
Collaboration agreement aggregate transaction price				$ 75,000,000
Upfront fee receivable upon signing contract				50,000,000
Collaboration agreement first anniversary amount receivable				$ 25,000,000
Collaboration agreement first anniversary payment received							25,000,000
Current portion of deferred revenue	27,800,000				27,800,000		27,800,000
Long-term portion of deferred revenue	37,900,000				37,900,000		$ 37,900,000
Apellis Pharmaceuticals, Inc | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration arrangement extension term				2 years
Pfizer
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Agreement description							In December 2021, the Company entered into a research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on the use of certain of the Company’s base editing technology to develop in vivo therapies for rare genetic diseases of the liver, muscle, and central nervous system. Under the terms of the Pfizer Agreement, the Company will conduct all research activities through development candidate selection for three base editing programs that target specific genes corresponding to specific diseases that are the subject of such programs. Pfizer will have exclusive rights to license each of the three programs at no additional cost, each an Opt-In Right, and will assume responsibility for subsequent development and commercialization. At the end of the Phase 1/2 clinical trials, the Company may elect to enter into a global co-development and co-commercialization agreement with Pfizer with respect to one program licensed under the collaboration for an option exercise fee equal to a percentage of the applicable development costs incurred by Pfizer, or the Participation Election. In the event the Company elects to exercise its Participation Election, upon the payment of its option exercise fee, Pfizer and the Company would share net profits as well as development and commercialization costs in a 65%/35% (Pfizer/Company) split for such program. The research collaboration is managed on an overall basis by a Joint Research Committee, or JRC, formed by an equal number of representatives from the Company and Pfizer.
Collaboration arrangement, initial term			4 years
Collaboration arrangement extension term description							extended for an additional year on a program-by-program basis
Potential total consideration			$ 1,350,000,000
Nonrefundable upfront payment receivable			300,000,000
Collaboration agreement upfront payment received		$ 300,000,000
Collaboration agreement performance obligation revenue recognized					12,800,000	$ 0	$ 33,400,000	$ 0
Collaboration agreement aggregate transaction price			$ 300,000,000
Earn-out payment period			10 years
Current portion of deferred revenue	123,600,000				123,600,000		123,600,000
Long-term portion of deferred revenue	$ 143,000,000				$ 143,000,000		$ 143,000,000
Pfizer | Assigned to Company | Upon Participation Election
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Net profits as well as development and commercialization costs percentage			35%
Pfizer | Assigned to Pfizer | Upon Participation Election
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Net profits as well as development and commercialization costs percentage			65%
Pfizer | Maximum | Per Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development regulatory and commercial milestones receivable			$ 350,000,000
Orbital
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock shares received at closing	75				75		75
Percentage of fully diluted equity interest	31.50%				31.50%		31.50%

Common Stock - Additional Infor

Common Stock - Additional Information (Details) - USD ($)		1 Months Ended	3 Months Ended					4 Months Ended	9 Months Ended	15 Months Ended
	Jan. 16, 2021	Apr. 30, 2021	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Jul. 31, 2021	Sep. 30, 2022	Sep. 30, 2022	Jul. 07, 2021
Class Of Stock [Line Items]
Common stock, voting rights									The holders of the Company’s common stock are entitled to one vote for each share of common stock.
Common Stock
Class Of Stock [Line Items]
Shares issued and sold			374,677	874,770	2,912,557	1,761,285	2,795,700
Jeffries LLC Sales Agreement
Class Of Stock [Line Items]
Gross proceeds from issuance of common stock								$ 300,000,000
Jeffries LLC Sales Agreement | Common Stock
Class Of Stock [Line Items]
Shares issued and sold								2,908,009
Price per share of stock sold								$ 103.16
Jeffries LLC Amended Sales Agreement
Class Of Stock [Line Items]
Gross proceeds from issuance of common stock									$ 289,300,000	$ 289,300,000
Jeffries LLC Amended Sales Agreement | Common Stock
Class Of Stock [Line Items]
Shares issued and sold										3,248,633
Price per share of stock sold									$ 89.06	$ 89.06
Private Placement
Class Of Stock [Line Items]
Gross proceeds from issuance of common stock	$ 260,000,000
Private Placement | Common Stock
Class Of Stock [Line Items]
Shares issued and sold	2,795,700
Price per share of shares issued	$ 93
Net proceeds from sale of common stock	$ 252,000,000
At-The-Market | Jeffries LLC Sales Agreement | Maximum
Class Of Stock [Line Items]
Aggregate gross proceeds of shares authorized under ATM sales agreement		$ 300,000,000
Commission rate		3%
At-The-Market | Jeffries LLC Amended Sales Agreement
Class Of Stock [Line Items]
Aggregate gross proceeds of shares authorized under ATM sales agreement											$ 500,000,000

Stock Option and Grant Plan - A

Stock Option and Grant Plan - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 29, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Oct. 31, 2019	May 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		$ 22,209,000	$ 12,968,000	$ 61,822,000	$ 28,068,000
Weighted-average grant date fair value per share of options granted				$ 41.84
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense related to unvested stock options		148,500,000		$ 148,500,000
Unrecognized compensation cost, cost to recognize over a weighted-average period				2 years 4 months 24 days
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation cost, cost to recognize over a weighted-average period				3 years 2 months 12 days
Unrecognized stock-based compensation expense, expected to vest		$ 98,300,000		$ 98,300,000
Restricted Stock | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period				4 years
Restricted Stock | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period				2 years
2017 Plan | Stock Options and Restricted Stock | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of shares for future issuance							8,078,681
2019 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of shares for future issuance						3,700,000
Number of shares reserved for future issuance		10,947,167		10,947,167
Number of shares available for future issuance		1,703,263		1,703,263
2019 Plan | Common Stock | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Annual percentage increase in shares authorized				4%
2019 Plan | Including 2017 Plan Shares | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of shares for future issuance						5,639,818
2019 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for future issuance		1,665,199		1,665,199
Number of shares issued		41,083		70,073	0
Stock-based compensation expense		$ 200,000	$ 0	$ 1,100,000	$ 0
Common stock, shares description				In February 2020, the Company’s board of directors adopted the Beam Therapeutics Inc. 2019 Employee Stock Purchase Plan, or ESPP, which was approved by the Company’s stockholders. Pursuant to the ESPP, certain employees of the Company, excluding consultants and non-employee directors, are eligible to purchase common stock of the Company at a reduced rate during offering periods. The ESPP permits participants to purchase common stock using funds contributed through payroll deductions, subject to a calendar year limit of $25,000 and at a purchase price of 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the applicable purchase date, which will be the final trading day of the applicable purchase period. The ESPP has two annual purchase periods extending from October to March and April to September.
Maximum amount allowed to purchase common stock using payroll deduction	$ 25,000
Percentage of common stock purchase price lower of the fair market value	85%

Stock Option and Grant Plan - S

Stock Option and Grant Plan - Summary of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 22,209	$ 12,968	$ 61,822	$ 28,068
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	13,859	7,554	38,581	17,049
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 8,350	$ 5,414	$ 23,241	$ 11,019

Stock Option and Grant Plan -_2

Stock Option and Grant Plan - Summary of Option Activity Under Equity Award Plans (Details) - $ / shares	9 Months Ended
	Sep. 30, 2022
Number of options
Outstanding at December 31, 2021	6,034,192
Granted	2,051,846
Exercised	(369,444)
Forfeitures	(109,531)
Outstanding at June 30, 2022	7,607,063
Exercisable as of June 30, 2022	3,421,139
Weighted average exercise price
Outstanding at December 31, 2021	$ 32.40
Granted	62.32
Exercised	5.33
Forfeitures	55.89
Outstanding at June 30, 2022	41.45
Exercisable as of June 30, 2022	$ 24.52

Stock Option and Grant Plan -_3

Stock Option and Grant Plan - Summary of Restricted Stock Activity (Details) - Restricted Stock	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Shares
Unvested as of December 31, 2021 | shares	1,126,206
Issued | shares	937,725
Vested | shares	(379,287)
Forfeited | shares	(36,865)
Unvested as of June 30, 2022 | shares	1,647,779
Weighted-average grant date fair value
Unvested as of December 31, 2021 | $ / shares	$ 74.32
Issued | $ / shares	53.52
Vested | $ / shares	51
Cancelled | $ / shares	75.65
Unvested as of June 30, 2022 | $ / shares	$ 67.82

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from computation of diluted net loss per share	9,254,842	7,426,084
Unvested Restricted Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from computation of diluted net loss per share	1,647,779	1,286,834
Outstanding Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from computation of diluted net loss per share	7,607,063	6,139,250

Net Loss per Share - Summary of

Net Loss per Share - Summary of Computation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator:
Net loss	$ (109,575)	$ (28,118)	$ (250,739)	$ (305,931)
Denominator:
Weighted average common shares outstanding, basic	70,343,196	66,377,611	69,758,434	62,960,219
Weighted average common shares outstanding, diluted	70,343,196	66,377,611	69,758,434	62,960,219
Net loss per common share , basic	$ (1.56)	$ (0.42)	$ (3.59)	$ (4.86)
Net loss per common share , diluted	$ (1.56)	$ (0.42)	$ (3.59)	$ (4.86)

Income taxes - Additional Infor

Income taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Provision for income tax	$ 2,410	$ 0	$ 2,410	$ 0
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards					$ 374,400
Operating loss carryforwards limitation percentage					80%

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details)	1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended
	Oct. 31, 2021 USD ($) ft²	Sep. 30, 2022 USD ($) shares	Sep. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Sep. 30, 2022 USD ($) Founder shares	Sep. 30, 2021 USD ($)	Jun. 30, 2021 shares
Related Party Transaction [Line Items]
Number of founder shareholders | Founder					3
Sublease income		$ 331,000			$ 993,000
Other income (expense)		10,431,000	$ (4,892,000)		(1,378,000)	$ 21,960,000
Office and Laboratory Space
Related Party Transaction [Line Items]
Operating lease term							12 years
Founder Shareholders | Scientific Consulting and Other Expenses
Related Party Transaction [Line Items]
Payments received from (made to) related parties		100,000	100,000		300,000	300,000
Verve Therapeutics, Inc.
Related Party Transaction [Line Items]
Equity securities		18,800,000			18,800,000
Other income (expense)		10,400,000	$ (4,900,000)		(1,400,000)	22,000,000
Verve Therapeutics, Inc. | Office and Laboratory Space
Related Party Transaction [Line Items]
Sublease area of rented space | ft²	12,000
Operating lease term	1 year
Sublease, commencement month and year	2021-12
Rental payment over term of sublease	$ 1,400,000
Sublease income		$ 300,000			$ 1,000,000
Verve Therapeutics, Inc. | Common Stock
Related Party Transaction [Line Items]
Equity shares held | shares		546,970			546,970		546,970
Verve Therapeutics, Inc. | Research and Development Expense
Related Party Transaction [Line Items]
Purchases from related party		$ 400,000			$ 400,000	$ 200,000
Reimbursed Costs | Prime Agreement | Interest and Other Income (Expense), Net | Prime Medicine Inc | Monthly Fee
Related Party Transaction [Line Items]
Income from related party				$ 30,000
Orbital
Related Party Transaction [Line Items]
Percentage of fully diluted equity interest		31.50%			31.50%